To O
investigate O
whether O
the O
tumor O
expression O
of O
beta B
- I
2 I
- I
microglobulin I
( O
beta B
2 I
- I
M I
) O
could O
serve O
as O
a O
marker O
of O
tumor O
biologic O
behavior O
, O
the O
authors O
studied O
specimens O
of O
breast O
carcinomas O
from O
60 O
consecutive O
female O
patients O
. O

No O
significant O
correlations O
were O
found O
between O
tumor B
beta I
2 I
- I
M I
expression O
and O
several O
histologic O
attributes O
such O
as O
type O
, O
histologic O
and O
nuclear O
grades O
, O
mitotic O
index O
, O
necrosis O
, O
vascular O
invasion O
, O
and O
lymphocytic O
infiltration O
. O

However O
, O
there O
was O
a O
significantly O
positive O
association O
between O
tumor B
beta I
2 I
- I
M I
expression O
and O
the O
degree O
of O
lymphocytic O
infiltration O
in O
the O
tumor O
tissue O
. O

Although O
some O
of O
the O
highest O
values O
had O
been O
obtained O
in O
women O
with O
larger O
( O
T4 O
) O
primary O
tumors O
, O
the O
authors O
failed O
to O
detect O
any O
statistical O
relationship O
between O
beta B
2 I
- I
M I
expression O
in O
the O
tumor O
with O
serum O
levels O
or O
between O
serum B
beta I
2 I
- I
M I
and O
the O
above O
histologic O
, O
laboratory O
, O
and O
clinical O
factors O
. O

[ O
Preliminary O
observation O
of O
level O
free B
- I
form I
E I
receptor I
levels O
in O
serum O
of O
normal O
childbearing O
- O
aged O
and O
pregnant O
women O
] O

Kappa B
B I
- I
specific I
DNA I
binding I
proteins I
: O
role O
in O
the O
regulation O
of O
human B
interleukin I
- I
2 I
gene I
expression O
. O

These O
kappa B
B I
- I
specific I
proteins I
( O
80 O
to O
90 O
and O
50 O
to O
55 O
kilodaltons O
) O
similarly O
interact O
with O
the O
functional O
kappa B
B I
enhancer I
present O
in O
the O
IL B
- I
2R I
alpha I
promoter I
. O

These O
kappa B
B I
- I
specific I
proteins I
( O
80 O
to O
90 O
and O
50 O
to O
55 O
kilodaltons O
) O
similarly O
interact O
with O
the O
functional O
kappa B
B I
enhancer I
present O
in O
the O
IL B
- I
2R I
alpha I
promoter I
. O

These O
data O
suggest O
that O
these O
kappa B
B I
- I
specific I
proteins I
have O
a O
role O
in O
the O
coordinate O
regulation O
of O
this O
growth O
factor O
- O
growth O
factor O
receptor O
gene O
system O
that O
controls O
T O
cell O
proliferation O
. O

Octamer B
- I
binding I
proteins I
from O
B O
or O
HeLa O
cells O
stimulate O
transcription O
of O
the O
immunoglobulin B
heavy I
- I
chain I
promoter I
in O
vitro O
. O

The O
B O
- O
cell O
- O
type O
specificity O
of O
the O
immunoglobulin B
( O
Ig B
) O
heavy O
- O
chain O
and O
light O
- O
chain O
promoters O
is O
mediated O
by O
an O
octanucleotide B
( I
OCTA I
) I
element I
, O
ATGCAAAT O
, O
that O
is O
also O
a O
functional O
component O
of O
other O
RNA B
polymerase I
II I
promoters I
, O
such O
as O
snRNA O
and O
histone O
H2B O
promoters O
. O

Identification O
of O
a O
putative O
regulator O
of O
early B
T I
cell I
activation I
genes I
. O

Molecules O
involved O
in O
the O
antigen O
receptor O
- O
dependent O
regulation O
of O
early B
T I
cell I
activation I
genes I
were O
investigated O
with O
the O
use O
of O
functional O
sequences O
of O
the O
T B
cell I
activation I
- I
specific I
enhancer I
of O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
. O

Octamer O
transcription O
factors O
1 O
and O
2 O
each O
bind O
to O
two O
different O
functional B
elements I
in O
the O
immunoglobulin B
heavy I
- I
chain I
promoter I
. O

Immunoglobulin B
heavy I
- I
chain I
genes I
contain O
two O
conserved B
sequence I
elements I
5 O
' O
to O
the O
site O
of O
transcription O
initiation O
: O
the O
octamer O
ATGCAAAT O
and O
the O
heptamer O
CTCATGA O
. O

Both O
of O
these O
elements O
are O
required O
for O
normal B
cell I
- I
specific I
promoter I
function O
. O

The O
present O
study O
demonstrates O
that O
both O
the O
ubiquitous B
and I
lymphoid I
- I
cell I
- I
specific I
octamer I
transcription I
factors I
( O
OTF B
- I
1 I
and O
OTF B
- I
2 I
, O
respectively O
) O
interact O
specifically O
with O
each O
of O
the O
two O
conserved B
sequence I
elements I
, O
forming O
either O
homo B
- I
or I
heterodimeric I
complexes I
. O

However O
, O
OTF B
interaction O
with O
the O
heptamer B
sequence I
appeared O
to O
require O
the O
presence O
of O
an O
intact O
octamer O
motif O
and O
occurred O
with O
a O
spacing O
of O
either O
2 B
or I
14 I
base I
pairs I
between O
the O
two O
elements O
, O
suggesting O
coordinate O
binding O
resulting O
from O
protein O
- O
protein O
interactions O
. O

Identification O
of O
a O
novel O
lymphoid B
specific I
octamer I
binding I
protein I
( O
OTF B
- I
2B I
) O
by O
proteolytic O
clipping O
bandshift O
assay O
( O
PCBA O
) O
. O

An O
apparent O
paradox O
is O
that O
the O
same O
sequence O
serves O
as O
an O
upstream B
promoter I
or I
enhancer I
element I
in O
a O
variety O
of O
housekeeping B
genes I
such O
as O
the O
histone B
H2B I
and I
U I
snRNA I
genes I
. O

` O
` O
Footprint O
' O
' O
and O
methylation O
- O
interference O
analyses O
have O
shown O
that O
purified O
NF B
- I
kappa I
B I
has O
a O
binding O
activity O
specific O
for O
the O
kappa B
light I
chain I
enhancer I
sequence I
. O

It O
is O
of O
particular O
interest O
in O
immunoglobulin B
genes I
since O
it O
is O
found O
in O
the O
upstream B
regions I
of O
all O
heavy B
and I
light I
chain I
promoters I
and O
in O
the O
heavy B
chain I
enhancer I
, O
both O
of O
which O
are O
known O
to O
be O
necessary O
for O
cell O
- O
specific O
expression O
. O

The O
specific O
DNA O
binding O
activity O
of O
the O
pure O
B B
cell I
- I
specific I
factor I
was O
indistinguishable O
from O
that O
of O
the O
affinity B
- I
purified I
ubiquitous I
factor I
. O

The O
specific O
DNA O
binding O
activity O
of O
the O
pure O
B B
cell I
- I
specific I
factor I
was O
indistinguishable O
from O
that O
of O
the O
affinity B
- I
purified I
ubiquitous I
factor I
. O

Interaction O
of O
cell B
- I
type I
- I
specific I
nuclear I
proteins I
with O
immunoglobulin B
VH I
promoter I
region I
sequences I
. O

This O
octanucleotide O
, O
in O
reverse O
orientation O
, O
is O
also O
found O
in O
all O
light B
chain I
variable I
region I
( I
VL I
) I
genes I
, O
and O
in O
the O
immunoglobulin B
heavy I
chain I
transcriptional I
enhancer I
. O

Preferential O
transcription O
of O
HTLV B
- I
I I
LTR I
in O
cell O
- O
free O
extracts O
of O
human O
T O
cells O
producing O
HTLV B
- I
I I
viral I
proteins I
. O

The O
promoters B
of O
the O
adenovirus B
2 I
major I
late I
gene I
, O
the O
mouse B
beta I
- I
globin I
gene I
, O
the O
mouse B
immunoglobulin I
VH I
gene I
and O
the O
LTR B
of O
the O
human O
T O
- O
lymphotropic O
retrovirus O
type O
I O
were O
tested O
for O
their O
transcription O
activities O
in O
cell O
- O
free O
extracts O
of O
four O
cell O
lines O
; O
HeLa O
, O
CESS O
( O
Epstein O
- O
Barr O
virus O
- O
transformed O
human O
B O
cell O
line O
) O
, O
MT O
- O
1 O
( O
HTLV O
- O
I O
- O
infected O
human O
T O
cell O
line O
without O
viral O
protein O
synthesis O
) O
, O
and O
MT O
- O
2 O
( O
HTLV O
- O
I O
- O
infected O
human O

The O
promoters B
of O
the O
adenovirus B
2 I
major I
late I
gene I
, O
the O
mouse B
beta I
- I
globin I
gene I
, O
the O
mouse B
immunoglobulin I
VH I
gene I
and O
the O
LTR B
of O
the O
human O
T O
- O
lymphotropic O
retrovirus O
type O
I O
were O
tested O
for O
their O
transcription O
activities O
in O
cell O
- O
free O
extracts O
of O
four O
cell O
lines O
; O
HeLa O
, O
CESS O
( O
Epstein O
- O
Barr O
virus O
- O
transformed O
human O
B O
cell O
line O
) O
, O
MT O
- O
1 O
( O
HTLV O
- O
I O
- O
infected O
human O
T O
cell O
line O
without O
viral O
protein O
synthesis O
) O
, O
and O
MT O
- O
2 O
( O
HTLV O
- O
I O
- O
infected O
human O

Acetylation O
and O
modulation O
of O
erythroid B
Kruppel I
- I
like I
factor I
( O
EKLF B
) O
activity O
by O
interaction O
with O
histone B
acetyltransferases I
. O

Erythroid B
Kruppel I
- I
like I
factor I
( O
EKLF B
) O
is O
a O
red B
cell I
- I
specific I
transcriptional I
activator I
that O
is O
crucial O
for O
consolidating O
the O
switch O
to O
high O
levels O
of O
adult O
beta O
- O
globin O
expression O
during O
erythroid O
ontogeny O
. O

EKLF B
is O
required O
for O
integrity O
of O
the O
chromatin O
structure O
at O
the O
beta B
- I
like I
globin I
locus I
, O
and O
it O
interacts O
with O
a O
positive B
- I
acting I
factor I
in O
vivo O
. O

These O
results O
establish O
EKLF B
as O
a O
tissue B
- I
specific I
transcription I
factor I
that O
undergoes O
post O
- O
translational O
acetylation O
and O
suggest O
a O
mechanism O
by O
which O
EKLF B
is O
able O
to O
alter O
chromatin O
structure O
and O
induce O
beta O
- O
globin O
expression O
within O
the O
beta B
- I
like I
globin I
cluster I
. O

These O
results O
establish O
EKLF B
as O
a O
tissue B
- I
specific I
transcription I
factor I
that O
undergoes O
post O
- O
translational O
acetylation O
and O
suggest O
a O
mechanism O
by O
which O
EKLF B
is O
able O
to O
alter O
chromatin O
structure O
and O
induce O
beta O
- O
globin O
expression O
within O
the O
beta B
- I
like I
globin I
cluster I
. O

To O
determine O
the O
effects O
on O
transcriptional O
regulation O
, O
U937 O
cells O
were O
transfected O
with O
a O
plasmid O
containing O
the O
HIV B
- I
1 I
enhancer I
( O
bearing O
two O
NF B
- I
kappa I
B I
sites I
) O
coupled O
to O
a O
chloramphenicol B
acetyltransferase I
( I
CAT I
) I
reporter I
. O

The O
extracellular O
domain O
of O
the O
murine B
G I
- I
CSF I
receptor I
was O
required O
for O
the O
activity O
of O
SB O
247464 O
, O
suggesting O
that O
the O
compound O
acts O
by O
oligomerizing B
receptor I
chains I
. O

Using O
the O
reverse O
transcription O
- O
polymerase O
chain O
reaction O
( O
RT O
) O
assay O
, O
the O
limit O
of O
detection O
was O
10 O
( O
- O
5 O
) O
to O
10 O
( O
- O
6 O
) O
for O
PML B
/ I
RAR I
alpha I
transcript I
and O
10 O
( O
- O
4 O
) O
to O
10 O
( O
- O
5 O
) O
for O
the O
AML1 B
/ I
ETO I
transcript I
. O

It O
was O
also O
determined O
, O
using O
electrophoresis O
mobility O
shift O
assays O
, O
that O
M O
. O
tuberculosis O
ManLAM O
led O
to O
the O
nuclear O
translocation O
of O
the O
transcription B
factor I
NF I
- I
kappaB I
. O

Sequence O
analysis O
of O
nineteen O
LTRs B
cloned O
from O
2 O
adult O
and O
3 O
pediatric O
patients O
revealed O
an O
average O
of O
33 O
nucleotide O
changes O
( O
with O
respect O
to O
the O
sequence O
of O
the O
LAI B
LTR I
) O
within O
the O
455 B
- I
bp I
U3 I
region I
. O

HMG B
box I
containing I
transcription I
factors I
in O
lymphocyte O
differentiation O
. O

Transcriptional O
regulation O
by O
C B
/ I
EBP I
alpha I
and I
- I
beta I
in O
the O
expression O
of O
the O
gene O
for O
the O
MRP14 B
myeloid I
calcium I
binding I
protein I
. O

Among O
several O
known O
transcription B
factor I
binding I
motifs I
, O
nuclear B
protein I
( I
s I
) I
of O
VD3 O
- O
treated O
HL O
- O
60 O
cells O
and O
THP O
- O
1 O
cells O
bound O
to O
the O
CCAAT B
/ I
enhancer I
binding I
protein I
( I
C I
/ I
EBP I
) I
- I
binding I
motif I
that O
was O
located O
in O
the O
upstream B
region I
of O
the O
MRP14 B
gene I
( O
- O
81 O
) O
, O
as O
evidenced O
by O
the O
competitive O
gel O
mobility O
- O
shift O
assay O
. O

Appropriate O
sized O
transcripts B
were O
detected O
in O
both O
cultured O
and O
fresh O
peripheral O
lymphocytes O
for O
CYP11A B
, O
CYP17 B
, O
HSD11L B
( O
11beta B
- I
hydroxysteroid I
dehydrogenase I
I I
) O
, O
HSD17B1 B
( O
17beta B
- I
hydroxysteroid I
dehydrogenase I
type I
I I
) O
and O
SRD5A1 B
( O
5alpha B
- I
reductase I
I I
) O
. O

It O
is O
a O
pterin B
4alpha I
- I
carbinolamine I
dehydratase I
that O
is O
involved O
in O
the O
regeneration O
of O
the O
cofactor B
tetrahydrobiopterin I
during O
the O
phenylalanine O
hydroxylase O
- O
catalyzed O
hydroxylation O
of O
phenylalanine O
. O

In O
this O
report O
the O
biochemical O
properties O
of O
the O
heterotrimeric B
NF I
- I
Y I
complex I
have O
been O
characterized O
during O
stage O
- O
specific O
B O
- O
cell O
development O
, O
and O
in O
several O
class O
II O
- O
mutant O
B O
- O
cell O
lines O
, O
which O
represent O
distinct O
bare O
lymphocyte O
syndrome O
class O
II O
genetic O
complementation O
groups O
. O

The O
NF B
- I
Y I
complex I
derived O
from O
class O
II O
+ O
mature O
B O
- O
cells O
bound O
with O
high O
affinity O
to O
anion B
exchangers I
, O
and O
eluted O
as O
an O
intact O
trimeric B
complex I
, O
whereas O
, O
NF B
- I
Y I
derived O
from O
class O
II O
- O
plasma O
B O
- O
cells O
, O
and O
from O
bare O
lymphocyte O
syndrome O
group O
II O
cell O
lines O
, O
RJ2 O
. O
2 O
. O
5 O
and O
RM3 O
, O
dissociated O
into O
discrete O
NF B
- I
YA I
and O
NF B
- I
YB I
: I
C I
subunit B
fractions I
. O

Recombination O
of O
the O
native B
NF I
- I
YA I
: I
B I
: I
C I
complex I
with O
the O
transcriptional B
cofactor I
, O
PC4 B
, O
likewise O
conferred O
high B
affinity I
NF I
- I
Y I
binding O
to O
anion B
exchangers I
, O
and O
stabilized O
NF B
- I
Y I
interaction O
with O
CCAAT B
- I
box I
DNA I
motifs I
in O
vitro O
. O

Recombination O
of O
the O
native B
NF I
- I
YA I
: I
B I
: I
C I
complex I
with O
the O
transcriptional B
cofactor I
, O
PC4 B
, O
likewise O
conferred O
high B
affinity I
NF I
- I
Y I
binding O
to O
anion B
exchangers I
, O
and O
stabilized O
NF B
- I
Y I
interaction O
with O
CCAAT B
- I
box I
DNA I
motifs I
in O
vitro O
. O

Induction O
of O
early B
B I
cell I
factor I
( O
EBF B
) O
and O
multiple B
B I
lineage I
genes I
by O
the O
basic B
helix I
- I
loop I
- I
helix I
transcription I
factor I
E12 B
. O

Our O
data O
demonstrate O
that O
, O
in O
the O
context O
of O
this O
macrophage O
line O
, O
E12 B
induces O
expression O
of O
EBF B
and O
together O
these O
transcription B
factors I
coordinately O
regulate O
numerous O
B B
lineage I
- I
associated I
genes I
. O

Nucleotide O
sequence O
analysis O
identified O
the O
5 B
' I
end I
of O
this O
RNA B
as O
human B
retinoid I
receptor I
RXRalpha I
mRNA I
. O

The O
current O
study O
aimed O
to O
investigate O
the O
immunohistochemical O
expression O
of O
matrix B
metalloproteinase I
3 I
( O
MMP B
- I
3 I
, O
stromelysin B
- I
1 I
) O
in O
correlation O
with O
the O
expression O
of O
Basement B
Membrane I
( I
BM I
) I
antigen I
( O
type B
IV I
collagen I
, O
laminin B
) O
, O
fibronectin B
, O
cathepsin B
D I
, O
p53 B
, O
c B
- I
erbB I
- I
2 I
, O
proliferative O
activity O
( O
Ki B
- I
67 I
, O
PCNA B
) O
, O
steroid O
receptor O
content O
as O
well O
as O
to O
the O
other O
conventional O
clinicopathological O
parameters O
in O
breast O
cancer O
. O

This O
study O
was O
performed O
on O
a O
series O
of O
frozen O
and O
paraffin O
sections O
from O
84 O
breast O
cancer O
specimens O
by O
immunohistochemistry O
using O
the O
monoclonal B
antibody I
MMP I
- I
3 I
( O
Ab B
- I
1 I
) O
. O

A O
significantly O
positive O
correlation O
was O
found O
between O
ST1 B
expression O
, O
and O
p53 B
tumour O
suppressor O
gene O
product O
( O
p O
= O
0 O
. O
004 O
) O
, O
and O
a O
relationship O
with O
c B
- I
erbB I
- I
2 I
protein O
and O
progesterone O
receptor O
status O
was O
also O
indicated O
. O

We O
have O
demonstrated O
previously O
that O
in O
a O
murine O
model O
of O
normobaric O
hypoxia O
pulmonary O
fibrin B
deposition O
is O
a O
result O
of O
expression O
of O
tissue B
factor I
, O
especially O
in O
oxygen B
- I
deprived I
mononuclear I
phagocytes I
( O
MPs B
) O
. O

A O
central O
role O
for O
Egr B
- I
1 I
in O
hypoxia O
- O
mediated O
tissue O
factor O
expression O
was O
confirmed O
by O
experiments O
with O
homozygous O
Egr B
- I
1 I
null O
mice O
; O
wild O
- O
type O
mice O
subjected O
to O
oxygen B
deprivation I
expressed I
tissue I
factor I
and O
showed O
fibrin B
deposition O
, O
but O
hypoxic O
homozygous O
Egr B
- I
1 I
null O
mice O
displayed O
neither O
tissue B
factor I
nor O
fibrin B
. O

Anti O
- O
CD3 O
- O
restimulated O
T O
cells O
( O
mainly O
CD8 O
+ O
) O
produced O
IL B
- I
2 I
, O
interferon B
- I
gamma I
( O
IFN B
- I
gamma I
) O
and O
tumour B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
and O
low O
levels O
of O
IL B
- I
4 I
and I
IL I
- I
10 I
transcripts I
and O
proteins O
. O

The O
presence O
of O
oxLDL O
is O
associated O
with O
activation O
of O
the O
transcription B
factor I
nuclear B
factor I
- I
kappaB I
in O
the O
endothelium O
as O
well O
as O
endothelial O
expression O
of O
intercellular B
adhesion I
molecule I
- I
1 I
. O

Chloramphenicol B
acetyltransferase I
reporter O
assays O
using O
the O
region O
upstream O
of O
the O
NF B
- I
kappaB I
- I
like I
elements I
identified O
an O
upstream O
region O
that O
reduced O
transcription O
from O
cognate B
and I
noncognate I
core I
promoters I
in O
a O
Tax O
- O
independent O
manner O
. O

beta B
- I
Amyloid I
fibrils I
activate O
parallel O
mitogen B
- I
activated I
protein I
kinase I
pathways O
in O
microglia O
and O
THP1 O
monocytes O
. O

Importantly O
, O
the O
stress B
- I
activated I
protein I
kinases I
( O
SAPKs B
) O
were O
not O
significantly O
activated O
in O
response O
to O
Abeta B
. O

Regulation O
of O
cellular B
retinoic I
acid I
binding I
protein I
( O
CRABP B
II I
) O
during O
human O
monocyte O
differentiation O
in O
vitro O
. O

Cellular B
retinoic I
acid I
binding I
proteins I
( O
CRABP B
) O
are O
low B
molecular I
weight I
proteins I
whose O
precise O
function O
remains O
unknown O
. O

PCNA B
transcription O
is O
regulated O
in O
part O
through O
tandem O
CRE B
sequences I
in O
the O
promoter B
and I
CRE I
binding I
proteins I
; O
IL B
- I
2 I
stimulates O
CREB O
phosphorylation O
in O
the O
resting O
cloned O
T O
lymphocyte O
, O
L2 O
. O

Elevated O
expression O
of O
differentiation B
inhibitory I
factor I
nm23 I
mRNA I
in O
monoblastic O
crisis O
of O
a O
patient O
with O
chronic O
myelogenous O
leukemia O
. O

Immunoglobulin B
( I
Ig I
) I
genes I
are O
hypermutated O
in O
B O
lymphocytes O
that O
are O
the O
precursors O
to O
memory O
B O
cells O
. O

Analysis O
of O
the O
nuclear B
c I
- I
Rel I
protein I
indicated O
that O
after O
anti O
- O
CD3 O
+ O
anti O
- O
CD28 O
stimulation O
the O
level O
of O
c B
- I
Rel I
was O
higher O
in O
CD45RA O
+ O
cells O
. O

They O
are O
intimately O
involved O
in O
regulating O
the O
transcription O
of O
the O
huMIP B
- I
1 I
alpha I
gene I
in O
monocytes O
, O
T O
- O
cells O
, O
and O
transformed O
B O
- O
cells O
. O

Bcl B
- I
3 I
in O
nuclear O
extracts O
of O
TF O
- O
1 O
cells O
bound O
to O
a O
kappaB B
enhancer I
in O
the O
c B
- I
myb I
promoter I
together O
with O
NF B
- I
kappaB2 I
/ I
p52 I
and O
this O
binding O
activity O
was O
enhanced O
by O
GM B
- I
CSF I
stimulation O
. O

5 B
- I
Lipoxygenase I
compartmentalization O
in O
granulocytic O
cells O
is O
modulated O
by O
an O
internal B
bipartite I
nuclear I
localizing I
sequence I
and O
nuclear B
factor I
kappa I
B I
complex I
formation O
. O

5 B
- I
Lipoxygenase I
compartmentalization O
in O
granulocytic O
cells O
is O
modulated O
by O
an O
internal B
bipartite I
nuclear I
localizing I
sequence I
and O
nuclear B
factor I
kappa I
B I
complex I
formation O
. O

A O
region O
of O
basic O
amino O
acids O
spanning O
residues B
639 I
- I
656 I
in O
the O
human B
5 I
- I
lipoxygenase I
sequence I
resembles O
a O
consensus B
bipartite I
nuclear I
localizing I
sequence I
. O

A O
region O
of O
basic O
amino O
acids O
spanning O
residues B
639 I
- I
656 I
in O
the O
human B
5 I
- I
lipoxygenase I
sequence I
resembles O
a O
consensus B
bipartite I
nuclear I
localizing I
sequence I
. O

Our O
results O
implicate O
an O
internal B
bipartite I
nuclear I
localizing I
sequence I
as O
a O
regulatory O
domain O
that O
modulates O
5 B
- I
lipoxygenase I
redistribution O
and O
catalysis O
in O
granulocytic O
cells O
. O

Cotransfection O
assays O
with O
the O
TR3 B
/ I
nur77 I
promoter I
sequence I
or O
the O
NBRE B
binding O
motif O
together O
with O
a O
series O
of O
Tax B
mutants O
have O
shown O
that O
Tax B
- O
induced O
TR3 B
/ I
nur77 I
expression O
is O
mediated O
by O
CREB B
/ I
ATF I
- I
related I
transcription I
factors I
. O

These O
findings O
reveal O
an O
intracellular O
signaling O
mechanism O
whereby O
a O
protein B
serine I
- I
threonine I
kinase I
( O
CaMKIV B
) O
is O
regulated O
by O
a O
tightly O
associated O
protein B
serine I
- I
threonine I
phosphatase I
( O
PP2A B
) O
. O

These O
findings O
reveal O
an O
intracellular O
signaling O
mechanism O
whereby O
a O
protein B
serine I
- I
threonine I
kinase I
( O
CaMKIV B
) O
is O
regulated O
by O
a O
tightly O
associated O
protein B
serine I
- I
threonine I
phosphatase I
( O
PP2A B
) O
. O

Insufficient O
glycemic O
control O
increases O
nuclear B
factor I
- I
kappa I
B I
binding O
activity O
in O
peripheral O
blood O
mononuclear O
cells O
isolated O
from O
patients O
with O
type O
1 O
diabetes O
. O

In O
the O
present O
study O
, O
we O
demonstrate O
that O
HIV B
- I
1 I
envelope I
glycoproteins I
of O
both O
T O
- O
cell O
- O
tropic O
and O
macrophagetropic O
strains O
rapidly O
activate O
the O
ERK O
/ O
mitogen O
- O
activated O
protein O
( O
MAP O
) O
kinase O
pathway O
and O
the O
binding O
of O
nuclear B
transcription I
factors I
( O
AP B
- I
1 I
, O
NF B
- I
kappaB I
, O
and O
C B
/ I
EBP I
) O
and O
stimulate O
expression O
of O
cytokine B
and I
chemokine I
genes I
. O

These O
results O
provide O
firm O
molecular O
evidence O
that O
binding O
of O
HIV B
- I
1 I
envelope I
glycoproteins I
to O
CD4 B
receptor I
initiates O
a O
signaling O
pathway O
( O
s O
) O
independent O
of O
the O
binding O
to O
the O
chemokine B
receptor I
that O
leads O
to O
the O
aberrant O
expression O
of O
inflammatory B
genes I
and O
may O
contribute O
significantly O
to O
HIV O
- O
1 O
replication O
as O
well O
as O
to O
deregulation O
of O
the O
immune O
system O
. O

Deregulation O
of O
bcl B
- I
6 I
expression O
by O
chromosomal O
rearrangements O
and O
point O
mutations O
of O
the O
bcl B
- I
6 I
promoter I
region I
are O
implicated O
in O
the O
pathogenesis O
of O
B O
- O
cell O
lymphoma O
. O

Here O
we O
show O
that O
antigen O
receptor O
activation O
leads O
to O
BCL B
- I
6 I
phosphorylation O
by O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
. O

We O
find O
that O
the O
alternatively O
spliced O
E12 B
and I
E47 I
bHLH I
proteins I
of O
the O
E2A B
gene I
play O
similar O
and O
additive O
roles O
in O
supporting O
B O
lymphopoiesis O
. O

Biased O
dependency O
of O
CD80 B
versus O
CD86 B
in O
the O
induction O
of O
transcription B
factors I
regulating O
the O
human B
IL I
- I
2 I
promoter I
. O

In O
most O
NB O
cell O
lines O
, O
both O
the O
DR3 B
and I
the I
DR3L I
sequences I
are O
simultaneously O
deleted O
and O
/ O
or O
translocated O
to O
another O
chromosome B
. O

Glucocorticoid O
inhibition O
of O
urokinase B
- I
like I
plasminogen I
activators I
in O
cultured O
human O
lymphoblasts O
. O

Lymphocytes O
from O
adult O
, O
neonatally O
DES O
- O
treated O
female O
mice O
have O
a O
reduced O
mitogen O
response O
to O
ConA B
and O
LPS B
( O
T B
and I
B I
cell I
mitogen I
) O
and O
the O
delayed O
type O
hypersensitivity O
response O
is O
depressed O
. O

Concentrations O
of O
cytosol B
and I
nuclear I
estrogen I
receptors I
( O
ERC B
and O
ERN B
, O
respectively O
) O
and O
progestin B
receptors I
( O
PRC B
and O
PRN B
) O
were O
also O
measured O
from O
endometrial O
biopsies O
taken O
on O
the O
24th O
day O
of O
the O
control O
and O
treatment O
cycle O
. O

In O
human O
T O
- O
cell O
lymphotropic O
virus O
- O
I O
infected O
cells O
, O
the O
Mr O
42 O
, O
000 O
long O
open B
reading I
frame I
protein I
encoded O
in O
part O
by O
the O
pX B
region I
of O
this O
virus O
may O
act O
as O
a O
transacting B
transcriptional I
activator I
that O
induces O
IL B
- I
2 I
receptor I
gene I
transcription O
, O
thus O
providing O
an O
explanation O
for O
the O
constant O
association O
of O
IL B
- I
2 I
receptor I
expression O
with O
adult O
T O
- O
cell O
lymphotropic O
virus O
- O
I O
infection O
of O
lymphoid O
cells O
. O

Based O
on O
these O
findings O
, O
it O
is O
concluded O
that O
both O
receptor O
types O
( O
cell B
membrane I
and I
cytoplasmic I
receptors I
) O
are O
being O
formed O
and O
increased O
at O
G1 O
phase O
prior O
to O
cell O
proliferation O
, O
indicating O
the O
importance O
of O
G1 O
phase O
in O
immunoregulation O
. O

These O
antibodies B
also O
recognized O
rat O
liver O
and O
murine B
S49 I
cell I
glucocorticoid I
receptors I
. O

Specific B
high I
- I
affinity I
receptors I
for O
1 O
, O
25 O
- O
dihydroxyvitamin O
D3 O
in O
human O
peripheral O
blood O
mononuclear O
cells O
: O
presence O
in O
monocytes O
and O
induction O
in O
T O
lymphocytes O
following O
activation O
. O

There O
was O
a O
positive O
correlation O
between O
the O
inflammatory O
infiltration O
and O
the O
presence O
of O
HLA B
class I
- I
I I
antigens I
on O
tumor O
cell O
s O
. O

A O
study O
of O
the O
receptors O
for O
dihydrotestosterone O
in O
fibroblasts O
of O
genital O
and O
nongenital O
skin O
showed O
a O
normal O
concentration O
of O
receptors O
in O
genital O
skin O
; O
5 B
- I
alpha I
- I
reductase I
activity O
in O
fibroblasts O
of O
the O
genital O
skin O
was O
low O
, O
but O
the O
plasma O
relationship O
testosterone O
/ O
dihydrotestosterone O
under O
HCG O
stimulation O
was O
normal O
. O

Activity O
of O
terminal B
deoxynucleotidyl I
transferase I
( O
TdT B
) O
, O
adenosine B
deaminase I
, O
and O
5 B
' I
nucleotidase I
and O
the O
cellular O
concentration O
of O
glucocorticoid B
( I
dexamethasone I
) I
receptor I
were O
determined O
in O
25 O
patients O
with O
acute O
non O
- O
lymphocytic O
leukaemia O
. O

A O
controlled O
pore O
glass O
bead O
assay O
for O
the O
measurement O
of O
cytoplasmic B
and I
nuclear I
glucocorticoid I
receptors I
. O

An O
assay O
for O
the O
quantitation O
of O
cytoplasmic B
and I
nuclear I
glucocorticoid I
receptors I
in O
lymphoid O
tissue O
has O
been O
developed O
using O
controlled O
pore O
glass O
( O
CPG O
) O
beads O
. O

The O
functional O
status O
of O
the O
steroid B
receptors I
was O
confirmed O
by O
nuclear O
transfer O
of O
the O
cytoplasmic B
hormone I
- I
receptor I
complex I
upon O
temperature O
activation O
. O

Intracytoplasmic B
corticosteroid I
- I
specific I
receptors I
appear O
to O
be O
an O
important O
common O
pathway O
for O
steroid O
- O
induced O
changes O
, O
but O
variations O
of O
receptor O
parameters O
do O
not O
account O
for O
the O
multifaceted O
effects O
on O
the O
immune O
system O
. O

Cytoplasmic B
steroid I
- I
receptor I
complexes I
exhibited O
a O
wide O
range O
of O
sedimentation O
coefficients O
( O
8 O
. O
5 O
- O
11 O
. O
3S O
) O
in O
low O
ionic O
strength O
buffer O
but O
there O
was O
no O
correlation O
with O
cell O
line O
type O
or O
glucocorticoid O
sensitivity O
. O

Analysis O
of O
the O
nuclear B
c I
- I
Rel I
protein I
indicated O
that O
after O
anti O
- O
CD3 O
+ O
anti O
- O
CD28 O
stimulation O
the O
level O
of O
c B
- I
Rel I
was O
higher O
in O
CD45RA O
+ O
cells O
. O

Overexpression O
of O
Rel B
proteins I
demonstrated O
that O
p65 O
- O
expressing O
Jurkat O
cells O
transcribed O
equally O
well O
a O
nuclear B
factor I
kappabeta I
reporter I
construct I
when O
costimulated O
with O
B7 B
- I
1 I
or O
LFA B
- I
3 I
, O
but O
transcription O
of O
IL B
- I
2 I
promoter I
or O
CD28 B
response I
element I
( I
CD28RE I
) I
- I
driven I
reporters I
was O
superior O
in O
B7 O
- O
1 O
- O
costimulated O
cells O
. O

We O
have O
studied O
the O
events O
underlying O
cap O
formation O
using O
mice O
bearing O
a O
null O
mutation O
in O
vav B
( O
vav B
- O
/ O
- O
) O
, O
a O
gene O
that O
encodes O
a O
guanine B
- I
nucleotide I
exchange I
factor I
for O
the O
GTPase B
Rac I
. O

Activation O
of O
Jun B
N I
- I
terminal I
kinase I
or O
stress B
- I
activated I
kinase I
( O
JNK B
or O
SAPK B
) O
and O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
and O
the O
induction O
of O
the O
transcription B
factor I
NF B
- I
ATc1 I
and I
egr I
- I
1 I
genes I
was O
normal O
. O

Activation O
of O
Jun B
N I
- I
terminal I
kinase I
or O
stress B
- I
activated I
kinase I
( O
JNK B
or O
SAPK B
) O
and O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
and O
the O
induction O
of O
the O
transcription B
factor I
NF B
- I
ATc1 I
and I
egr I
- I
1 I
genes I
was O
normal O
. O

The O
heterodimeric O
Ku B
protein I
, O
which O
comprises O
a O
86 B
kDa I
( I
Ku86 I
) I
amd O
a O
70 B
kDa I
( I
Ku70 I
) I
subunits I
, O
is O
an O
abundant O
nuclear B
DNA I
- I
binding I
protein I
which O
binds O
in O
vitro O
to O
DNA B
termini I
without O
sequence O
specificity O
. O

The O
heterodimeric O
Ku B
protein I
, O
which O
comprises O
a O
86 B
kDa I
( I
Ku86 I
) I
amd O
a O
70 B
kDa I
( I
Ku70 I
) I
subunits I
, O
is O
an O
abundant O
nuclear B
DNA I
- I
binding I
protein I
which O
binds O
in O
vitro O
to O
DNA B
termini I
without O
sequence O
specificity O
. O

By O
using O
electrophoretic O
mobility O
shift O
assays O
, O
we O
demonstrated O
that O
in O
addition O
to O
the O
major B
Ku I
x I
DNA I
complex I
usually O
detected O
in O
cell O
line O
extracts O
, O
a O
second O
complex O
with O
faster O
electrophoretic O
mobility O
was O
observed O
in O
normal O
peripheral O
blood O
lymphocytes O
( O
PBL O
) O
extracts O
. O

Co O
- O
stimulation O
of O
human O
peripheral O
blood O
mononuclear O
cells O
with O
IL B
- I
2 I
and O
anti B
- I
CD3 I
monoclonal I
antibodies I
induces O
phosphorylation O
of O
CREB B
. O

In O
particular O
, O
the O
transcription B
factor I
PU I
. I
1 I
has O
a O
critical O
role O
in O
this O
process O
. O

In O
addition O
, O
many O
effects O
of O
LKLF B
expression O
were O
mimicked O
by O
expression O
of O
the O
dominant B
- I
negative I
MadMyc I
protein I
and O
rescued O
by O
overexpression O
of O
c B
- I
Myc I
. O

The O
p12 B
( I
I I
) I
protein I
, O
encoded O
by O
the O
pX B
open I
reading I
frame I
I I
of O
the O
human O
T O
- O
lymphotropic O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
, O
is O
a O
hydrophobic B
protein I
that O
localizes O
to O
the O
endoplasmic O
reticulum O
and O
the O
Golgi O
. O

The O
p12 B
( I
I I
) I
protein I
, O
encoded O
by O
the O
pX B
open I
reading I
frame I
I I
of O
the O
human O
T O
- O
lymphotropic O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
, O
is O
a O
hydrophobic B
protein I
that O
localizes O
to O
the O
endoplasmic O
reticulum O
and O
the O
Golgi O
. O

Glucocorticoid B
- I
regulated I
transcription I
factors I
. O

Inhibition O
of O
pro B
- I
inflammatory I
transcription I
factors I
such O
as O
activator B
protein I
( I
AP I
) I
- I
1 I
, O
signal B
transducers I
and I
activators I
of I
transcription I
( O
STATs B
) O
, O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
and O
nuclear B
factor I
( I
NF I
) I
- I
kappa I
B I
is O
thought O
to O
be O
a O
major O
action O
of O
glucocorticoids O
. O

This O
induction O
was O
accompanied O
by O
augmented O
expression O
of O
the O
class B
B I
scavenger I
receptor I
CD36 I
( O
2 O
. O
8 O
+ O
/ O
- O
0 O
. O
3 O
- O
fold O
, O
P O
< O
0 O
. O
001 O
) O
but O
not O
by O
increased O
peroxisome B
proliferator I
- I
activated I
receptor I
- I
gamma I
expression O
. O

Peritoneal O
macrophages O
seem O
to O
participate O
in O
the O
process O
of O
peritoneal O
fibrosis O
and O
monocyte B
chemoattractant I
protein I
- I
1 I
( O
MCP B
- I
1 I
) O
plays O
a O
key O
role O
in O
the O
recruitment O
of O
monocytes O
toward O
the O
peritoneal O
cavity O
. O

LMP1 B
acts O
like O
a O
constitutively B
activated I
receptor I
of O
the O
tumor B
necrosis I
factor I
receptor I
family I
and O
allows O
the O
amplification O
or O
bypassing O
of O
physiological O
regulatory O
signals O
through O
direct O
and O
indirect O
interactions O
with O
proteins O
of O
the O
tumor B
necrosis I
factor I
receptor I
- I
associated I
factor I
( I
TRAF I
) I
family I
. O

Activation O
of O
the O
p21 B
( I
CIP1 I
/ I
WAF1 I
) I
promoter I
by O
bone B
morphogenetic I
protein I
- I
2 I
in O
mouse O
B O
lineage O
cells O
. O

We O
also O
examined O
whether O
signaling O
by O
muramyl O
peptides O
involves O
the O
use O
of O
cell B
surface I
receptors I
, O
including O
CD14 B
and O
Toll B
- I
like I
receptor I
2 I
( O
TLR2 B
) O
or O
TLR4 B
that O
are O
known O
to O
be O
signal B
- I
transducing I
receptors I
for O
other O
bacterial O
cell O
wall O
components O
. O

We O
demonstrate O
that O
, O
unlike O
LPS O
, O
the O
safe O
immunomodulator O
MB O
selectively O
activates O
extracellular B
signal I
- I
regulated I
kinases I
( I
Erk I
) I
1 I
/ I
2 I
, O
in O
the O
absence O
of O
detectable O
Jun B
N I
- I
terminal I
kinase I
( O
JNK B
) O
or O
p38 B
mitogen I
- I
activated I
kinase I
activation O
. O

We O
demonstrate O
that O
, O
unlike O
LPS O
, O
the O
safe O
immunomodulator O
MB O
selectively O
activates O
extracellular B
signal I
- I
regulated I
kinases I
( I
Erk I
) I
1 I
/ I
2 I
, O
in O
the O
absence O
of O
detectable O
Jun B
N I
- I
terminal I
kinase I
( O
JNK B
) O
or O
p38 B
mitogen I
- I
activated I
kinase I
activation O
. O

The O
U937 O
cells O
transiently O
transfected O
with O
a O
PPAR B
response I
element I
luciferase I
reporter I
showed O
disease O
stage O
- O
dependent O
up O
- O
regulation O
when O
treated O
with O
peritoneal O
fluid O
from O
patients O
with O
endometriosis O
. O

Long O
- O
term O
- O
impaired O
expression O
of O
nuclear B
factor I
- I
kappa I
B I
and O
I B
kappa I
B I
alpha I
in O
peripheral O
blood O
mononuclear O
cells O
of O
trauma O
patients O
. O

Although O
no O
direct O
correlation O
was O
found O
between O
levels O
of O
interleukin B
- I
10 I
or O
transforming B
growth I
factor I
- I
beta I
and O
NF B
- I
kappa I
B I
, O
these O
immunosuppressive B
cytokines I
were O
significantly O
elevated O
in O
trauma O
patients O
by O
10 O
days O
after O
admission O
. O

Keywords O
included O
reperfusion O
injury O
, O
transplantation O
, O
liver O
resection O
, O
nitric O
oxide O
, O
endothelin O
, O
cytokines B
, O
Kupffer O
cells O
, O
ischemic O
/ O
ischaemic O
preconditioning O
, O
and O
nuclear B
factor I
- I
kappa I
B I
. O

Activation O
of O
nuclear B
factor I
- I
kappa I
B I
in O
the O
liver O
promotes O
proinflammatory B
cytokine I
and O
adhesion B
molecule I
synthesis O
. O

Down O
- O
regulation O
of O
IL B
- I
12 I
p40 I
gene I
in O
Plasmodium O
berghei O
- O
infected O
mice O
. O

We O
analyzed O
the O
mechanism O
that O
causes O
suppression O
of O
IL B
- I
12 I
p40 I
gene I
induction O
during O
Plasmodium O
berghei O
infection O
. O

Although O
IL B
- I
12 I
together O
with O
IFN B
- I
gamma I
plays O
an O
important O
role O
in O
protection O
against O
pathogenic O
infection O
, O
the O
IL B
- I
12 I
p70 I
protein I
production O
of O
infected O
macrophages O
is O
lower O
than O
that O
by O
the O
uninfected O
macrophages O
. O

We O
showed O
in O
the O
present O
study O
that O
the O
induction O
of O
IL B
- I
12 I
p40 I
gene I
but O
not O
IL B
- I
12 I
p35 I
gene I
in O
macrophages O
of O
P O
. O
berghei O
- O
infected O
mice O
was O
profoundly O
inhibited O
. O

We O
showed O
in O
the O
present O
study O
that O
the O
induction O
of O
IL B
- I
12 I
p40 I
gene I
but O
not O
IL B
- I
12 I
p35 I
gene I
in O
macrophages O
of O
P O
. O
berghei O
- O
infected O
mice O
was O
profoundly O
inhibited O
. O

Therefore O
, O
the O
inhibition O
of O
the O
IL B
- I
12 I
p40 I
gene I
induction O
appeared O
to O
be O
regulated O
at O
transcriptional O
regulation O
level O
of O
the O
gene O
. O

However O
, O
after O
inhibition O
of O
the O
PI3K B
/ O
Akt B
- I
1 I
pathway O
, O
a O
marked O
decrease O
in O
the O
expression O
of O
the O
antiapoptotic B
molecule I
Mcl B
- I
1 I
, O
but O
not O
other O
Bcl B
- I
2 I
family I
members I
was O
observed O
, O
and O
Mcl B
- I
1 I
rescued O
macrophages O
from O
LY294002 O
- O
induced O
cell O
death O
. O

Galectin B
- I
10 I
( O
gal B
- I
10 I
, O
also O
known O
as O
Charcot B
- I
Leyden I
crystal I
protein I
) O
is O
a O
member O
of O
the O
galectin B
family I
of O
beta B
- I
galactoside I
binding I
proteins I
that O
is O
expressed O
uniquely O
in O
eosinophilic O
and O
basophilic O
leukocytes O
. O

Galectin B
- I
10 I
( O
gal B
- I
10 I
, O
also O
known O
as O
Charcot B
- I
Leyden I
crystal I
protein I
) O
is O
a O
member O
of O
the O
galectin B
family I
of O
beta B
- I
galactoside I
binding I
proteins I
that O
is O
expressed O
uniquely O
in O
eosinophilic O
and O
basophilic O
leukocytes O
. O

Constitutive O
expression O
of O
MHC B
class I
II I
genes I
in O
melanoma O
cell O
lines O
results O
from O
the O
transcription O
of O
class B
II I
transactivator I
abnormally O
initiated O
from O
its O
B B
cell I
- I
specific I
promoter I
. O

We O
report O
here O
that O
the O
60 B
- I
kDa I
catalytic I
subunit I
of O
calcineurin B
A I
( O
Cn B
A I
) O
was O
partially O
cleaved O
to O
a O
45 B
- I
kDa I
form O
in O
phytohemagglutinin O
A O
( O
PHA O
) O
or O
phorbol O
ester O
+ O
ionomycin O
( O
P O
+ O
I O
) O
- O
activated O
Jurkat O
cells O
. O

This O
defect O
prevents O
the O
proteolytic O
processing O
required O
for O
the O
production O
and O
activation O
of O
the O
transcription B
factor I
nuclear I
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
, O
which O
plays O
important O
roles O
in O
immune O
and O
inflammatory O
responses O
, O
as O
well O
as O
increases O
the O
susceptibility O
of O
the O
affected O
cells O
to O
apoptosis O
induced O
by O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
. O

Binding O
and O
competition O
experiments O
demonstrate O
that O
Ikaros B
dimers I
compete O
with O
an O
Ets B
activator I
for O
occupancy O
of O
the O
lymphocyte B
- I
specific I
TdT I
promoter I
. O

Therapeutic O
use O
of O
type B
I I
IFN I
( O
IFN B
- I
alpha I
/ I
beta I
) O
has O
become O
common O
. O

The O
ability O
of O
IFN B
- I
alpha I
/ I
beta I
to O
suppress O
IL O
- O
12 O
production O
while O
up O
- O
regulating O
IFN O
- O
gamma O
production O
suggests O
a O
possible O
mechanistic O
basis O
for O
the O
difficulties O
of O
employing O
these O
cytokines B
in O
diseases O
involving O
abnormalities O
of O
CMI O
. O

To O
test O
these O
properties O
in O
humans O
, O
we O
investigated O
the O
effect O
of O
troglitazone O
on O
the O
proinflammatory B
transcription I
factor I
nuclear I
factor I
- I
kappaB I
and O
its O
inhibitory B
protein I
IkappaB I
in O
mononuclear O
cells O
( O
MNC O
) O
and O
plasma B
soluble I
intracellular I
adhesion I
molecule I
- I
1 I
, O
monocyte B
chemoattractant I
protein I
- I
1 I
, O
plasminogen B
activator I
inhibitor I
- I
1 I
, O
and O
C B
- I
reactive I
protein I
. O

To O
test O
these O
properties O
in O
humans O
, O
we O
investigated O
the O
effect O
of O
troglitazone O
on O
the O
proinflammatory B
transcription I
factor I
nuclear I
factor I
- I
kappaB I
and O
its O
inhibitory B
protein I
IkappaB I
in O
mononuclear O
cells O
( O
MNC O
) O
and O
plasma B
soluble I
intracellular I
adhesion I
molecule I
- I
1 I
, O
monocyte B
chemoattractant I
protein I
- I
1 I
, O
plasminogen B
activator I
inhibitor I
- I
1 I
, O
and O
C B
- I
reactive I
protein I
. O

Reactive O
oxygen O
species O
generation O
by O
polymorphonuclear O
cells O
and O
MNC O
, O
p47 B
( I
phox I
) I
subunit I
protein I
quantities O
, O
plasminogen B
activator I
inhibitor I
- I
1 I
, O
and O
C B
- I
reactive I
protein I
levels O
decreased O
significantly O
after O
troglitazone O
intake O
. O

Transient O
transfection O
assays O
of O
the O
human B
osteopontin I
promoter I
/ I
luciferase I
construct I
which O
contains O
a O
5 B
' I
- I
flanking I
region I
between O
- O
1500 O
and O
+ O
87 O
relative O
to O
the O
transcription B
start I
site I
demonstrate O
that O
either O
treatment O
with O
troglitazone O
or O
cotransfection O
of O
PPARgamma B
expression I
vector I
inhibits O
osteopontin O
promoter O
activity O
. O

In O
contrast O
to O
the O
Igkappa B
locus I
, O
known O
transcriptional B
control I
elements I
in O
the O
Iglambda B
locus I
lack O
functional O
NF B
- I
kappaB I
binding I
sites I
. O

Transcription B
factor I
STAT5A B
is O
a O
substrate O
of O
Bruton B
' I
s I
tyrosine I
kinase I
in O
B O
cells O
. O

Here O
we O
show O
that O
STAT5A B
can O
serve O
as O
a O
functional O
substrate O
of O
Bruton B
' I
s I
tyrosine I
kinase I
( O
BTK B
) O
. O

Recombinant B
BTK I
proteins I
with O
mutant O
pleckstrin O
homology O
, O
SH2 B
, I
or I
SH3 I
domains I
were O
capable O
of O
phosphorylating O
STAT5A B
, O
whereas O
recombinant B
BTK I
proteins I
with O
SH1 O
/ O
kinase O
domain O
mutations O
were O
not O
. O

In O
pull O
- O
down O
experiments O
, O
only O
full B
- I
length I
BTK I
and O
its O
SH1 B
/ I
kinase I
domain I
( O
but O
not O
the O
pleckstrin O
homology O
, O
SH2 B
, I
or I
SH3 I
domains I
) O
were O
capable O
of O
binding O
STAT5A B
. O

BTK B
- O
mediated O
tyrosine O
phosphorylation O
of O
ectopically O
expressed O
wild O
type O
( O
but O
not O
Tyr B
( I
694 I
) I
mutant I
) O
STAT5A B
enhanced O
its O
DNA O
binding O
activity O
. O

B O
cell O
antigen O
receptor O
ligation O
resulted O
in O
enhanced O
tyrosine O
phosphorylation O
of O
STAT5 B
in O
BTK B
- O
deficient O
chicken O
B O
cells O
reconstituted O
with O
wild B
type I
human I
BTK I
but O
not O
in O
BTK B
- O
deficient O
chicken O
B O
cells O
reconstituted O
with O
kinase B
- I
inactive I
mutant I
BTK I
. O

We O
show O
that O
T B
- I
bet I
, O
without O
apparent O
assistance O
from O
interleukin B
12 I
( I
IL I
- I
12 I
) I
/ O
STAT4 B
, O
specifies O
TH1 O
effector O
fate O
by O
targeting O
chromatin O
remodeling O
to O
individual O
interferon B
- I
gamma I
( I
IFN I
- I
gamma I
) I
alleles I
and O
by O
inducing O
IL B
- I
12 I
receptor I
beta2 I
expression O
. O

In O
response O
to O
IL B
- I
4 I
, O
the O
IL B
- I
4R I
activates O
a O
set O
of O
phosphotyrosine B
binding I
domain I
- I
containing I
proteins I
, O
including O
insulin B
receptor I
substrate I
1 I
/ I
2 I
, O
Shc B
, O
and O
IL B
- I
4R I
interacting I
protein I
, O
as O
well O
as O
Stat6 B
. O

The O
effect O
of O
HIV B
- I
1 I
regulatory I
proteins I
on O
cellular O
genes O
: O
derepression O
of O
the O
IL B
- I
2 I
promoter I
by O
Tat B
. O

Tat B
derepresses O
and O
activates O
the O
distal B
AP I
- I
1 I
site I
( O
position B
- I
185 I
to I
- I
177 I
) O
in O
the O
IL B
- I
2 I
promoter I
. O

Transforming B
growth I
factor I
- I
beta1 I
interferes O
with O
thrombopoietin O
- O
induced O
signal O
transduction O
in O
megakaryoblastic O
and O
erythroleukemic O
cells O
. O

TPO B
- O
induced O
proliferation O
also O
was O
reduced O
by O
a O
specific O
inhibitor O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
pathway O
( O
PD098059 O
) O
, O
which O
inhibits O
activation O
of O
the O
MAPK B
extracellular I
signal I
- I
regulated I
kinases I
( O
ERK B
) O
ERK1 B
and O
ERK2 B
, O
and O
AG490 O
, O
an O
inhibitor O
of O
Janus B
kinase I
- I
2 I
, O
which O
completely O
blocked O
TPO B
- O
induced O
proliferation O
. O

Our O
studies O
indicate O
that O
Ii B
- O
induced O
B O
cell O
maturation O
involves O
activation O
of O
transcription O
mediated O
by O
the O
NF B
- I
kappaB I
p65 I
/ I
RelA I
homodimer I
and O
requires O
the O
B B
cell I
- I
enriched I
coactivator I
TBP B
- I
associated I
factor I
( I
II I
) I
105 I
. O

Functional O
correction O
of O
FA O
- O
C O
cells O
with O
FANCC B
suppresses O
the O
expression O
of O
interferon B
gamma I
- I
inducible I
genes I
. O

High O
constitutive O
expression O
of O
the O
IFNgamma B
- I
inducible I
genes I
, O
IFN B
- I
stimulated I
gene I
factor I
3 I
gamma I
subunit I
( O
ISGF3gamma B
) O
, O
IFN B
regulatory I
factor I
- I
1 I
( O
IRF B
- I
1 I
) O
, O
and O
the O
cyclin B
- I
dependent I
kinase I
inhibitor I
p21 I
( O
WAF1 B
) O
was O
found O
in O
FANCC B
mutant O
B O
lymphoblasts O
, O
low O
- O
density O
bone O
marrow O
cells O
, O
and O
murine O
embryonic O
fibroblasts O
. O

In O
an O
attempt O
to O
clarify O
mechanisms O
by O
which O
FA O
- O
C O
cells O
overexpress O
IFNgamma B
- I
inducible I
genes I
in O
the O
face O
of O
defective O
STAT1 O
phosphorylation O
, O
it O
was O
reasoned O
that O
decreased O
levels O
of O
activated B
STAT1 I
might O
result O
in O
reduced O
expression O
of O
a O
hematopoietic B
IFNgamma I
- I
responsive I
protein I
that O
normally O
modulates O
expression O
of O
other O
IFNgamma B
- I
responsive I
genes I
. O

Levels O
of O
the O
IFNgamma B
- O
inducible O
factor O
IFN B
consensus I
sequence I
binding I
protein I
( O
ICSBP B
) O
, O
a O
negative B
trans I
- I
acting I
regulator I
of O
some O
IFNgamma B
- I
inducible I
genes I
, O
were O
quantified O
. O

Levels O
of O
the O
IFNgamma B
- O
inducible O
factor O
IFN B
consensus I
sequence I
binding I
protein I
( O
ICSBP B
) O
, O
a O
negative B
trans I
- I
acting I
regulator I
of O
some O
IFNgamma B
- I
inducible I
genes I
, O
were O
quantified O
. O

These O
committed O
lymphoid O
cells O
must O
then O
undergo O
V O
( O
D O
) O
J O
recombination O
at O
the O
immunoglobulin B
gene I
or O
T B
cell I
receptor I
gene I
locus I
resulting O
in O
clonal O
production O
of O
functional O
B O
or O
T O
lymphocytes O
, O
respectively O
. O

One O
of O
the O
most O
prominent O
glucocorticoid O
- O
induced O
genes B
is O
glucocorticoid B
- I
induced I
leucine I
zipper I
( O
GILZ B
) O
, O
which O
has O
been O
reported O
to O
inhibit O
activation O
- O
induced O
up O
- O
regulation O
of O
Fas B
ligand I
( I
FasL I
) I
mRNA I
. O

This O
could O
be O
accounted O
for O
by O
GILZ B
- O
mediated O
inhibition O
of O
Egr B
- I
2 I
and O
Egr B
- I
3 I
, O
NFAT B
/ I
AP I
- I
1 I
- O
inducible O
transcription B
factors I
that O
bind O
a O
regulatory B
element I
in O
the O
FasL B
promoter I
and O
up O
- O
regulate O
FasL O
expression O
. O

Whereas O
homodimerization O
of O
GILZ B
required O
the O
presence O
of O
its O
leucine B
zipper I
, O
the O
interaction O
with O
c B
- I
Fos I
and O
c B
- I
Jun I
occurred O
through O
the O
N B
- I
terminal I
60 B
- I
amino I
acid I
region I
of O
GILZ B
. O

Smad3 B
and O
Smad4 B
mediate O
transforming B
growth I
factor I
- I
beta1 I
- O
induced O
IgA O
expression O
in O
murine O
B O
lymphocytes O
. O

The O
trans B
- I
activator I
protein I
Tax I
of O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
( O
HTLV O
- O
I O
) O
plays O
an O
important O
role O
in O
the O
development O
of O
adult O
T O
- O
cell O
leukemia O
through O
, O
at O
least O
in O
part O
, O
its O
ability O
to O
stimulate O
cell O
growth O
. O

Even O
more O
, O
coexpression O
of O
a O
dominant O
negative O
version O
of O
NFAT B
inhibited O
Cot B
kinase I
- O
mediated O
COX B
- I
2 I
promoter I
activation O
, O
whereas O
cotransfection O
of O
a O
constitutively O
active O
version O
of O
the O
calcium B
- I
dependent I
phosphatase I
calcineurin I
synergizes O
with O
Cot B
kinase I
in O
the O
up O
- O
regulation O
of O
COX B
- I
2 I
promoter I
- O
driven O
transcription O
. O

Strikingly O
, O
Cot B
kinase I
increased O
transactivation O
mediated O
by O
a O
GAL4 B
- I
NFAT I
fusion I
protein I
containing O
the O
N B
- I
terminal I
transactivation I
domain I
of O
NFATp B
. O

Strikingly O
, O
Cot B
kinase I
increased O
transactivation O
mediated O
by O
a O
GAL4 B
- I
NFAT I
fusion I
protein I
containing O
the O
N B
- I
terminal I
transactivation I
domain I
of O
NFATp B
. O

Members O
of O
the O
Ly B
- I
49 I
gene I
family I
code O
for O
class B
I I
MHC I
- I
specific I
receptors I
that O
regulate O
NK O
cell O
function O
. O

The O
acquisition O
of O
one O
Ly B
- I
49 I
receptor I
, O
Ly B
- I
49A I
is O
strictly O
dependent O
on O
the O
transcriptional B
trans I
- I
acting I
factor I
T B
cell I
- I
specific I
factor I
- I
1 I
( O
TCF B
- I
1 I
) O
. O

Besides O
reduced O
receptor O
usage O
( O
Ly B
- I
49A I
and I
D I
) O
, O
we O
also O
observed O
no O
effect O
( O
Ly B
- I
49C I
) O
and O
significantly O
expanded O
( O
Ly B
- I
49G I
and I
I I
) O
receptor O
usage O
in O
the O
absence O
of O
TCF B
- I
1 I
. O

Besides O
reduced O
receptor O
usage O
( O
Ly B
- I
49A I
and I
D I
) O
, O
we O
also O
observed O
no O
effect O
( O
Ly B
- I
49C I
) O
and O
significantly O
expanded O
( O
Ly B
- I
49G I
and I
I I
) O
receptor O
usage O
in O
the O
absence O
of O
TCF B
- I
1 I
. O

Ligation O
of O
CD11b B
and O
CD11c B
beta I
( I
2 I
) I
integrins B
by O
antibodies B
or O
soluble B
CD23 I
induces O
macrophage B
inflammatory I
protein I
1alpha I
( O
MIP B
- I
1alpha I
) O
and O
MIP B
- I
1beta I
production O
in O
primary O
human O
monocytes O
through O
a O
pathway O
dependent O
on O
nuclear B
factor I
- I
kappaB I
. O

We O
found O
that O
ligation O
of O
CD11b B
or O
CD11c B
but O
not O
CD11a B
alpha I
chains I
of O
beta B
( I
2 I
) I
integrins I
by O
antibodies B
or O
soluble B
CD23 I
( I
sCD23 I
) I
fusion I
proteins I
rapidly O
induced O
transcription O
and O
secretion O
of O
interleukin B
8 I
, O
macrophage B
inflammatory I
protein I
( I
MIP I
) I
1alpha I
, O
and O
MIP B
- I
1beta I
. O

Activation O
of O
NF B
- I
kappaB I
was O
accompanied O
by O
degradation O
of O
its O
cytosolic B
inhibitor I
IkappaB I
- I
alpha I
. O

These O
results O
suggest O
that O
triggering O
of O
CD11b B
or O
CD11c B
beta I
( I
2 I
) I
integrin O
on O
primary O
human O
monocytes O
provides O
activation O
signals O
leading O
to O
nuclear O
translocation O
of O
NF B
- I
kappaB I
and O
subsequent O
secretion O
of O
MIP B
- I
1alpha I
and O
MIP B
- I
1beta I
that O
may O
have O
an O
important O
role O
in O
recruitment O
of O
other O
inflammatory O
cells O
during O
initiation O
of O
an O
inflammatory O
response O

Human B
ACAT I
- I
1 I
gene I
contains O
two O
promoters B
( O
P1 B
and O
P7 B
) O
, O
each O
located O
in O
a O
different O
chromosome B
( I
1 I
and I
7 I
) I
( O
Li O
, O
B O
. O
L O
. O
, O
Li O
, O
X O
. O
L O
. O
, O
Duan O
, O
Z O
. O
J O
. O
, O
Lee O
, O
O O
. O
, O
Lin O
, O
S O
. O
, O
Ma O
, O
Z O
. O
M O
. O
, O
Chang O
, O
C O
. O
C O
. O
, O
Yang O
, O
X O
. O
Y O
. O
, O
Park O
, O
J O
. O
P O
. O
, O
Mohandas O
, O
T O
. O
K O
. O
, O
Noll O
, O
W O
. O
, O
Chan O
, O
L O
. O
, O
and O
Chang O
, O
T O
. O
Y O
. O
( O
1999 O
) O
J O
. O
Biol O
Chem O
. O

To O
examine O
the O
molecular O
nature O
of O
this O
observation O
, O
we O
identified O
within O
the O
ACAT B
- I
1 I
P1 I
promoter I
a O
159 B
- I
base I
pair I
core I
region I
. O

This O
region O
contains O
4 O
Sp1 B
elements I
and O
an O
IFN B
- I
gamma I
activated I
sequence I
( O
GAS B
) O
that O
overlaps O
with O
the O
second O
Sp1 B
element I
. O

In O
the O
monocytic O
cell O
line O
THP O
- O
1 O
cell O
, O
the O
combination O
of O
IFN B
- I
gamma I
and O
all O
- O
trans O
- O
retinoic O
acid O
( O
a O
known O
differentiation O
agent O
) O
enhances O
the O
ACAT B
- I
1 I
P1 I
promoter I
but O
not O
the O
P7 B
promoter I
. O

Additional O
experiments O
showed O
that O
all O
- O
trans O
- O
retinoic O
acid O
causes O
large O
induction O
of O
the O
transcription B
factor I
STAT1 I
, O
while O
IFN B
- I
gamma I
causes O
activation O
of O
STAT1 B
such O
that O
it O
binds O
to O
the O
GAS B
/ I
Sp1 I
site I
in O
the O
ACAT B
- I
1 I
P1 I
promoter I
. O

Recent O
studies O
in O
transgenic O
mice O
have O
revealed O
that O
expression O
of O
a O
dominant O
negative O
form O
of O
the O
transcription B
factor I
GATA I
- I
3 I
in O
T O
cells O
can O
prevent O
T O
helper O
cell O
type O
2 O
( O
Th2 O
) O
- O
mediated O
allergic O
airway O
inflammation O
in O
mice O
. O

Requirement O
for O
p38 B
and O
p44 B
/ I
p42 I
mitogen B
- I
activated I
protein I
kinases I
in O
RAGE B
- O
mediated O
nuclear B
factor I
- I
kappaB I
transcriptional O
activation O
and O
cytokine O
secretion O
. O

The O
NF O
- O
kappaB O
response O
was O
blocked O
with O
a O
synthetic O
peptide O
corresponding O
to O
the O
putative B
ligand I
- I
binding I
domain I
of O
RAGE B
, O
with O
anti O
- O
RAGE B
antiserum O
, O
and O
by O
coexpression O
of O
truncated B
receptors I
lacking O
the O
intracellular B
domain I
. O

Activation O
of O
NF B
- I
kappaB I
by O
CML B
- I
modified I
albumin I
increased O
secretion O
of O
proinflammatory B
cytokines I
( O
tumor B
necrosis I
factor I
- I
alpha I
, O
interleukin B
- I
1beta I
, O
and O
monocyte B
chemoattractant I
protein I
- I
1 I
) O
severalfold O
, O
and O
inhibition O
of O
p38 B
MAPK I
blocked O
these O
increases O
. O

Activation O
of O
NF B
- I
kappaB I
by O
CML B
- I
modified I
albumin I
increased O
secretion O
of O
proinflammatory B
cytokines I
( O
tumor B
necrosis I
factor I
- I
alpha I
, O
interleukin B
- I
1beta I
, O
and O
monocyte B
chemoattractant I
protein I
- I
1 I
) O
severalfold O
, O
and O
inhibition O
of O
p38 B
MAPK I
blocked O
these O
increases O
. O

In O
this O
report O
we O
address O
the O
role O
of O
phosphoinositide B
3 I
' I
- I
kinase I
( O
PI B
3 I
- I
kinase I
) O
in O
BCR B
- O
and O
LPS O
- O
induced O
NF O
- O
kappaB O
activation O
using O
populations O
of O
primary O
murine O
resting O
B O
cells O
. O

NF B
- I
kappaB I
and O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
activation O
were O
assessed O
by O
gel O
shift O
assay O
, O
and O
mRNA O
expression O
of O
interleukin B
- I
6 I
, O
tumor B
necrosis I
factor I
- I
alpha I
, O
KC O
, O
monocyte B
chemoattractant I
protein I
- I
1 I
, O
and O
inducible B
nitric I
oxide I
synthase I
was O
assessed O
by O
semiquantitative O
RT O
- O
PCR O
. O

NF B
- I
kappaB I
and O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
activation O
were O
assessed O
by O
gel O
shift O
assay O
, O
and O
mRNA O
expression O
of O
interleukin B
- I
6 I
, O
tumor B
necrosis I
factor I
- I
alpha I
, O
KC O
, O
monocyte B
chemoattractant I
protein I
- I
1 I
, O
and O
inducible B
nitric I
oxide I
synthase I
was O
assessed O
by O
semiquantitative O
RT O
- O
PCR O
. O

In O
experiments O
with O
the O
CD45R0 B
mAb I
UCHL I
- I
1 I
, O
but O
not O
control B
CD45 I
mAbs I
, O
we O
found O
significant O
inhibition O
of O
proliferation O
. O

Addition O
of O
CD3 B
mAb I
OKT I
- I
3 I
had O
no O
influence O
on O
IL O
- O
2 O
- O
mediated O
proliferation O
( O
with O
or O
without O
UCHL B
- I
1 I
) O
. O

Depletion O
of O
Vgamma1 O
( O
+ O
) O
cells O
using O
monoclonal B
anti I
- I
Vgamma1 I
antibody I
enhanced O
myocarditis O
and O
CD4 O
( O
+ O
) O
- O
, O
IFN B
- I
gamma I
( O
+ O
) O
- O
cell O
responses O
in O
both O
H3 O
- O
and O
H310A1 O
- O
infected O
mice O
yet O
decreased O
the O
CD4 O
( O
+ O
) O
- O
, O
IL O
- O
4 O
( O
+ O
) O
- O
cell O
response O
. O

Plasmin B
0 O
. O
043 O
to O
1 O
. O
43 O
CTA O
U O
/ O
mL O
, O
but O
not O
active B
site I
- I
blocked I
plasmin I
, O
triggered O
concentration O
- O
dependent O
expression O
of O
mRNA O
for O
interleukin B
- I
1alpha I
( O
IL B
- I
1alpha I
) O
, O
IL B
- I
1beta I
, O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
and O
TF B
with O
maximum O
responses O
after O
4 O
hours O
. O

Plasmin B
0 O
. O
043 O
to O
1 O
. O
43 O
CTA O
U O
/ O
mL O
, O
but O
not O
active B
site I
- I
blocked I
plasmin I
, O
triggered O
concentration O
- O
dependent O
expression O
of O
mRNA O
for O
interleukin B
- I
1alpha I
( O
IL B
- I
1alpha I
) O
, O
IL B
- I
1beta I
, O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
and O
TF B
with O
maximum O
responses O
after O
4 O
hours O
. O

Identification O
of O
phosphorylation B
sites I
for O
Bruton B
' I
s I
tyrosine I
kinase I
within O
the O
transcriptional B
regulator I
BAP I
/ I
TFII I
- I
I I
. O

Bruton B
' I
s I
tyrosine I
kinase I
( O
Btk B
) O
, O
a O
member O
of O
the O
Tec B
family I
of I
cytosolic I
kinases I
, O
is O
essential O
for O
B O
cell O
development O
and O
function O
. O

Bruton B
' I
s I
tyrosine I
kinase I
( O
Btk B
) O
, O
a O
member O
of O
the O
Tec B
family I
of I
cytosolic I
kinases I
, O
is O
essential O
for O
B O
cell O
development O
and O
function O
. O

BAP B
/ I
TFII I
- I
I I
, O
a O
protein O
implicated O
in O
transcriptional O
regulation O
, O
is O
associated O
with O
Btk B
in O
B O
cells O
and O
is O
transiently O
phosphorylated O
on O
tyrosine O
following O
B O
cell O
receptor O
engagement O
. O

BAP B
/ I
TFII I
- I
I I
is O
a O
substrate O
for O
Btk B
in O
vitro O
and O
is O
hyperphosphorylated O
on O
tyrosine O
upon O
coexpression O
with O
Btk B
in O
mammalian O
cells O
. O

In O
an O
effort O
to O
understand O
the O
physiologic O
consequences O
of O
BAP B
/ I
TFII I
- I
I I
tyrosine O
phosphorylation O
following O
B O
cell O
receptor O
stimulation O
, O
site O
- O
directed O
mutagenesis O
and O
phosphopeptide O
mapping O
were O
used O
to O
locate O
the O
predominant O
sites O
of O
BAP B
/ I
TFII I
- I
I I
phosphorylation O
by O
Btk B
in O
vitro O
. O

In O
an O
effort O
to O
understand O
the O
physiologic O
consequences O
of O
BAP B
/ I
TFII I
- I
I I
tyrosine O
phosphorylation O
following O
B O
cell O
receptor O
stimulation O
, O
site O
- O
directed O
mutagenesis O
and O
phosphopeptide O
mapping O
were O
used O
to O
locate O
the O
predominant O
sites O
of O
BAP B
/ I
TFII I
- I
I I
phosphorylation O
by O
Btk B
in O
vitro O
. O

These O
residues O
, O
Tyr248 O
, O
Tyr357 O
, O
and O
Tyr462 O
, O
were O
also O
found O
to O
be O
the O
major O
sites O
for O
Btk B
- O
dependent O
phosphorylation O
of O
BAP B
/ I
TFII I
- I
I I
in O
vivo O
. O

Residues O
Tyr357 O
and O
Tyr462 O
are O
contained O
within O
the O
loop B
regions I
of O
adjacent O
helix B
- I
loop I
- I
helix I
- I
like I
repeats I
within O
BAP B
/ I
TFII I
- I
I I
. O

Phosphorylation O
of O
BAP B
/ I
TFII I
- I
I I
by O
Btk B
may O
link O
engagement O
of O
receptors O
such O
as O
surface O
immunoglobulin B
to O
modulation O
of O
gene O
expression O
. O

Expression O
of O
interferon B
consensus I
sequence I
binding I
protein I
induces O
potent O
immunity O
against O
BCR O
/ O
ABL O
- O
induced O
leukemia O
. O

Mice O
deficient O
in O
the O
interferon B
consensus I
sequence I
binding I
protein I
( O
ICSBP B
) O
develop O
a O
disease O
resembling O
chronic O
myeloid O
leukemia O
( O
CML O
) O
, O
which O
in O
humans O
is O
caused O
by O
the O
BCR B
/ I
ABL I
oncoprotein I
. O

CD28 O
+ O
CD8 O
( O
+ O
) O
T O
cells O
unable O
to O
transcribe O
the O
IL B
- I
2 I
gene I
in O
response O
to O
antigenic O
stimulation O
had O
a O
block O
in O
transactivation O
of O
the O
- B
150 I
CD28 I
response I
element I
( I
CD28RE I
) I
/ I
AP I
- I
1 I
site I
of O
the O
IL B
- I
2 I
promoter I
, O
but O
did O
transactivate O
the O
composite O
NFAT B
/ I
AP I
- I
1 I
and I
OCT I
/ I
AP I
- I
1 I
sites I
, O
and O
a O
consensus B
AP I
- I
1 I
motif I
. O

Mutation O
of O
the O
nonconsensus B
- I
150 I
AP I
- I
1 I
site I
to O
a O
consensus B
AP I
- I
1 I
site I
, O
or O
insertion O
of O
a O
CD28RE B
/ I
AP I
- I
1 I
consensus I
site I
upstream O
of O
the O
native O
- B
150 I
CD28RE I
/ I
AP I
- I
1 I
site I
restored O
transactivation O
of O
the O
altered O
promoter B
. O

EBV O
binds O
to O
CR2 B
through O
its O
major B
envelope I
glycoprotein I
- I
350 I
( O
gp350 B
) O
and O
is O
also O
a O
remarkable O
immunomodulating O
agent O
. O

Both O
EBV O
and O
gp350 B
enhance O
the O
binding O
of O
the O
NF B
- I
kappaB I
transcription I
factor I
, O
as O
determined O
by O
band O
- O
shift O
and O
augment O
NF B
- I
kappaB I
- O
mediated O
activation O
of O
a O
CAT B
reporter I
plasmid I
. O

To O
our O
knowledge O
this O
is O
the O
first O
report O
showing O
that O
the O
binding O
of O
a O
herpesvirus B
envelope I
glycoprotein I
to O
CR2 B
on O
human O
B O
cells O
results O
in O
the O
activation O
of O
the O
NF B
- I
kappaB I
transcription I
factor I
leading O
to O
the O
upregulation O
of O
IL O
- O
6 O
gene O
expression O
in O
these O
lymphocytes O
. O

Caspase B
- O
dependent O
cleavage O
of O
the O
hematopoietic B
specific I
adaptor I
protein I
Gads I
alters O
signalling O
from O
the O
T B
cell I
receptor I
. O

Gads B
is O
a O
SH2 B
and I
SH3 I
domain I
- O
containing O
, O
hematopoietic B
- I
specific I
adaptor I
protein I
that O
functions O
in O
signalling O
from O
the O
T B
cell I
receptor I
. O

Gads B
is O
distinguished O
from O
Grb2 B
and O
the O
closely O
related O
Grap B
protein I
by O
the O
presence O
of O
a O
120 B
amino I
acid I
unique I
region I
between O
the O
SH2 B
domain I
and O
the O
carboxy B
terminal I
SH3 I
domain I
. O

A O
putative B
caspase I
3 I
cleavage I
site I
was O
identified O
within O
the O
unique O
region O
and O
mutation O
of O
this O
site O
prevented O
Gads B
cleavage O
in O
vitro O
, O
and O
in O
vivo O
. O

The O
intrinsic O
histone O
acetyltransferase O
activity O
of O
p300 B
is O
dispensable O
for O
activation O
of O
the O
IL B
- I
2 I
promoter I
, O
and O
the O
N B
- I
terminal I
743 I
residues I
contain O
the O
minimal O
structural O
requirements O
for O
synergistic O
transactivation O
of O
the O
CD28RE B
- I
TRE I
, O
the O
IL B
- I
2 I
promoter I
, O
and O
endogenous O
IL B
- I
2 I
gene I
expression O
. O

As O
an O
alternative O
to O
cytokine O
measurement O
, O
this O
study O
focuses O
on O
expression O
of O
the O
transcription B
factor I
GATA I
- I
3 I
for O
analysis O
of O
allergen O
- O
specific O
Th O
cell O
responses O
. O

The O
stress O
response O
( O
SR O
) O
can O
block O
inflammatory O
gene O
expression O
by O
preventing O
activation O
of O
transcription B
factor I
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappaB I
) O
. O

This O
approach O
uses O
reporter B
- I
plasmids I
for O
the O
detection O
of O
intracellular O
signals O
mediated O
by O
the O
mitogen B
- I
activated I
protein I
kinase I
or O
cyclic B
AMP I
- I
dependent I
protein I
kinase I
. O

Core B
- I
binding I
factor I
beta I
( O
CBFbeta B
) O
, O
but O
not O
CBFbeta B
- I
smooth I
muscle I
myosin I
heavy I
chain I
, O
rescues O
definitive O
hematopoiesis O
in O
CBFbeta B
- O
deficient O
embryonic O
stem O
cells O
. O

Core B
- I
binding I
factor I
beta I
( O
CBFbeta B
) O
is O
the O
non B
- I
DNA I
- I
binding I
subunit I
of O
the O
heterodimeric B
CBFs I
. O

Definitive O
hematopoiesis O
is O
restored O
by O
ectopic O
expression O
of O
full B
- I
length I
Cbfb I
transgenes I
, O
as O
well O
as O
by O
a O
transgene O
encoding O
only O
the O
heterodimerization B
domain I
of O
CBFbeta B
. O

Results O
also O
show O
that O
the O
CBFbeta B
- I
SMMHC I
fusion I
protein I
transdominantly O
inhibits O
definitive O
hematopoiesis O
, O
but O
not O
to O
the O
same O
extent O
as O
homozygous O
loss O
of O
Runx1 B
or O
Cbfb B
. O

The O
implication O
of O
EBV O
in O
the O
skin O
lesions O
was O
determined O
by O
the O
presence O
of O
EBV B
- I
DNA I
, O
EBV B
- I
encoded I
nuclear I
RNA I
( O
EBER B
) O
and O
a O
clonality O
of O
EBV B
- I
DNA I
fragments I
containing O
the O
terminal B
repeats I
. O

Our O
results O
indicate O
that O
the O
restricted O
expression O
of O
the O
latency B
- I
associated I
EBV I
genes I
and O
the O
production O
of O
vIL B
- I
10 I
and I
bcl I
- I
2 I
homologue I
may O
favour O
tumour O
growth O
, O
evading O
the O
host O
immune O
surveillance O
. O

To O
understand O
the O
mechanism O
by O
which O
the O
beta B
subunit I
expression O
is O
regulated O
, O
we O
cloned O
the O
MAT2B B
gene I
, O
determined O
its O
organization O
, O
characterized O
its O
5 B
' I
- I
flanking I
sequences I
, O
and O
elucidated O
the O
in O
vitro O
and O
in O
vivo O
regulation O
of O
its O
promoter B
. O

The O
data O
show O
that O
the O
5 B
' I
- I
untranslated I
sequences I
play O
an O
important O
role O
in O
regulating O
the O
MAT2B B
gene I
and O
identifies O
the O
Sp1 B
site I
at O
+ O
9 O
as O
a O
potential O
target O
for O
modulating O
MAT2B O
expression O
, O
a O
process O
that O
can O
have O
a O
major O
effect O
on O
intracellular O
AdoMet B
levels O
. O

Influenza O
A O
virus O
- O
induced O
IFN B
- I
alpha I
/ I
beta I
is O
essential O
in O
host O
' O
s O
antiviral O
defence O
by O
activating O
the O
expression O
of O
antiviral B
Mx I
, O
PKR B
and I
oligoadenylate I
synthetase I
genes I
. O

Influenza O
A O
virus O
- O
induced O
IFN B
- I
alpha I
/ I
beta I
is O
essential O
in O
host O
' O
s O
antiviral O
defence O
by O
activating O
the O
expression O
of O
antiviral B
Mx I
, O
PKR B
and I
oligoadenylate I
synthetase I
genes I
. O

IFN B
- I
alpha I
/ I
beta I
also O
prolongs O
T O
cell O
survival O
, O
upregulates O
IL O
- O
12 O
and O
IL O
- O
18 O
receptor O
gene O
expression O
and O
together O
with O
IL B
- I
18 I
stimulates O
NK O
and O
T O
cell O
IFN O
- O
gamma O
production O
and O
the O
development O
of O
Th1 O
- O
type O
immune O
response O
. O

Differential O
requirement O
for O
the O
transcription B
factor I
PU I
. I
1 I
in O
the O
generation O
of O
natural O
killer O
cells O
versus O
B O
and O
T O
cells O
. O

PU B
. I
1 I
is O
a O
member O
of O
the O
Ets B
family I
of I
transcription I
factors I
required O
for O
the O
development O
of O
various O
lymphoid O
and O
myeloid O
cell O
lineages O
, O
but O
its O
role O
in O
natural O
killer O
( O
NK O
) O
cell O
development O
is O
not O
known O
. O

We O
recently O
reported O
the O
SART3 B
tumour I
- I
rejection I
antigen I
as O
possessing O
tumour O
epitopes O
capable O
of O
inducing O
HLA O
- O
class O
I O
- O
restricted O
cytotoxic O
T O
lymphocytes O
( O
CTLs O
) O
. O

Autostimulation O
of O
the O
Epstein O
- O
Barr O
virus O
BRLF1 B
promoter I
is O
mediated O
through O
consensus O
Sp1 B
and I
Sp3 I
binding I
sites I
. O

Hypoxia B
inducible I
factor I
- I
1 I
( O
HIF B
- I
1 I
) O
is O
a O
constitutively O
expressed O
basic O
helix B
- I
loop I
- I
helix I
transcription I
factor I
, O
formed O
by O
the O
assembly O
of O
HIF B
- I
1alpha I
and O
HIF B
- I
1beta I
( O
Arnt B
) O
, O
that O
is O
stablized O
in O
response O
to O
hypoxia O
, O
and O
rapidly O
degraded O
under O
normoxic O
conditions O
. O

Here O
, O
we O
demonstrate O
that O
engineered O
down O
- O
regulation O
of O
HIF B
- I
1alpha I
by O
intratumoral O
gene O
transfer O
of O
an O
antisense B
HIF I
- I
1alpha I
plasmid I
leads O
to O
the O
down O
- O
regulation O
of O
VEGF B
, O
and O
decreased O
tumor O
microvessel O
density O
. O

However O
, O
no O
T B
- I
cell I
receptor I
gene I
rearrangement O
was O
identified O
in O
cultured O
progeny O
. O

Id B
- I
3 I
, O
a O
basic B
helix I
loop I
helix I
factor I
with O
dominant O
negative O
function O
for O
T O
- O
cell O
differentiation O
transcription B
factors I
, O
also O
was O
upregulated O
and O
may O
explain O
unsuccessful O
T O
- O
cell O
maturation O
. O

These O
results O
suggest O
that O
TCF B
- I
1 I
does O
not O
target O
human B
killer I
immunoglobulin I
receptor I
genes I
, O
TCF B
- I
1 I
is O
uniquely O
expressed O
in O
circulating O
CD56 O
( O
+ O
bright O
) O
NK O
cells O
, O
and O
specific O
TCF B
- I
1 I
isoforms I
may O
play O
an O
important O
role O
in O
regulating O
NK O
differentiation O
from O
a O
common O
NK O
/ O
T O
- O
cell O
progenitor O
. O

Similar O
to O
one O
group O
of O
high B
mobility I
group I
box I
proteins I
, O
Bright B
distorts O
E B
mu I
binding I
site I
- O
containing O
DNA O
on O
binding O
, O
supporting O
the O
concept O
that O
it O
mediates O
E B
mu I
remodeling O
. O

BCL B
- I
6 I
is O
essential O
for O
germinal O
center O
formation O
and O
thus O
for O
affinity O
maturation O
of O
immunoglobulin B
( I
Ig I
) I
genes I
by O
somatic O
mutations O
. O

The O
5 B
' I
- I
noncoding I
region I
of O
the O
BCL B
- I
6 I
gene I
is O
even O
a O
target O
for O
the O
mutation O
machinery O
. O

Decreased O
expression O
of O
c B
- I
myc I
family I
genes I
in O
thymuses O
from O
myasthenia O
gravis O
patients O
. O

We O
studied O
the O
expression O
of O
apoptosis O
- O
associated O
genes O
, O
bcl B
- I
xL I
, O
bad B
, O
caspase B
- I
3 I
, O
and O
c B
- I
myc I
family I
genes I
in O
myasthenia O
gravis O
( O
MG O
) O
thymuses O
. O

Activation O
of O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
pathways O
leads O
to O
cellular O
differentiation O
and O
/ O
or O
proliferation O
in O
a O
wide O
variety O
of O
cell O
types O
, O
including O
developing O
thymocytes O
. O

The O
differences O
in O
NF B
- I
kappa I
B I
transcriptional O
activity O
correlated O
with O
the O
generation O
of O
distinct O
NF B
- I
kappa I
B I
complexes I
. O

These O
observations O
suggest O
that O
fine O
regulation O
of O
NF B
- I
kappa I
B I
complex I
formation O
may O
determine O
T O
cell O
fate O
. O

To O
test O
this O
hypothesis O
, O
we O
targeted O
SHP B
- I
1 I
into O
lipid O
rafts O
by O
using O
the O
N B
- I
terminal I
region I
of I
Lck I
( O
residues B
1 I
- I
- I
14 I
) O
. O

Homocysteine O
stimulates O
the O
expression O
of O
monocyte B
chemoattractant I
protein I
- I
1 I
in O
endothelial O
cells O
leading O
to O
enhanced O
monocyte O
chemotaxis O
. O

Monocyte B
chemoattractant I
protein I
- I
1 I
( O
MCP B
- I
1 I
) O
is O
a O
potent O
chemokine B
that O
stimulates O
the O
migration O
of O
monocytes O
into O
the O
intima O
of O
the O
arterial O
wall O
. O

Terminal O
effectors O
of O
B O
cell O
Fas B
- O
resistance O
include O
the O
known O
anti B
- I
apoptotic I
gene I
products I
, O
Bcl B
- I
xL I
and O
FLIP B
, O
and O
a O
novel O
anti B
- I
apoptotic I
gene I
that O
encodes O
FAIM B
( O
Fas B
Apoptosis I
Inhibitory I
Molecule I
) O
. O

These O
studies O
suggest O
that O
NO O
- O
related O
signaling O
pathways O
may O
mediate O
SDF1 B
alpha I
- O
induced O
chemotaxis O
, O
but O
not O
mitogen B
- I
activated I
protein I
kinase I
activation O
. O

Deletion O
of O
autoreactive O
thymocytes O
at O
the O
DP O
stage O
is O
the O
basis O
for O
tolerance O
to O
thymus B
- I
expressed I
self I
antigens I
. O

Epstein O
- O
barr O
virus O
immediate B
- I
early I
protein I
BZLF1 I
is O
SUMO O
- O
1 O
modified O
and O
disrupts O
promyelocytic O
leukemia O
bodies O
. O

The O
PML B
protein I
is O
induced O
by O
interferon B
, O
involved O
in O
major B
histocompatibility I
complex I
class I
I I
presentation O
, O
and O
necessary O
for O
certain O
types O
of O
apoptosis O
. O

To O
examine O
whether O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
lytic O
replication O
interferes O
with O
PML O
bodies O
, O
we O
expressed O
the O
EBV B
immediate I
- I
early I
genes I
BZLF1 B
( I
Z I
) I
and O
BRLF1 B
( I
R I
) I
in O
EBV O
- O
positive O
cell O
lines O
and O
examined O
PML B
localization O
. O

We O
measured O
intranuclear B
NFkappaB I
, O
total O
cellular B
NFkappaB I
, O
inhibitor B
kappaB I
( I
IkappaB I
) I
alpha I
, O
reactive O
oxygen O
species O
( O
ROS O
) O
generation O
, O
and O
p47 B
( I
phox I
) I
subunit I
( O
a O
key O
component O
protein O
of O
nicotinamide B
adenine I
dinucleotide I
phosphate I
oxidase I
) O
in O
MNC O
. O

We O
measured O
intranuclear B
NFkappaB I
, O
total O
cellular B
NFkappaB I
, O
inhibitor B
kappaB I
( I
IkappaB I
) I
alpha I
, O
reactive O
oxygen O
species O
( O
ROS O
) O
generation O
, O
and O
p47 B
( I
phox I
) I
subunit I
( O
a O
key O
component O
protein O
of O
nicotinamide B
adenine I
dinucleotide I
phosphate I
oxidase I
) O
in O
MNC O
. O

Plasma B
tumor I
necrosis I
factor I
( I
TNF I
) I
- I
alpha I
, O
soluble B
intercellular I
adhesion I
molecule I
- I
1 I
( O
sICAM B
- I
1 I
) O
, O
monocyte B
chemoattractant I
protein I
- I
1 I
( I
MCP I
- I
1 I
) I
, O
plasminogen B
activator I
inhibitor I
type I
1 I
( O
PAI B
- I
1 I
) O
, O
C B
- I
reactive I
protein I
( I
CRP I
) I
, O
and O
interleukin B
( I
IL I
) I
- I
10 I
( O
antiinflammatory B
cytokine I
) O
concentrations O
were O
also O
measured O
as O
mediators O
of O
inflammatory O
activity O
that O
are O
regulated O
by O
the O
proinflammatory B
transcription I
factor I
NFkappaB I
. O

MNC O
were O
separated O
; O
and O
the O
levels O
of O
intranuclear B
NFkappaB I
, O
total O
cellular B
NFkappaB I
, O
IkappaBalpha B
, O
and O
p47 B
( I
phox I
) I
subunit I
and O
ROS O
generation O
were O
determined O
. O

There O
was O
a O
fall O
in O
intranuclear B
NFkappaB I
, O
total O
cellular B
NFkappaB I
, O
and O
p47 B
( I
phox I
) I
subunit I
, O
with O
an O
increase O
in O
cellular O
IkappaBalpha B
at O
week O
2 O
, O
which O
persisted O
until O
week O
4 O
. O

Phosphorylation O
of O
the O
N B
- I
terminal I
domain I
of O
I B
kappa I
B I
inhibitory I
subunits I
induces O
activation O
of O
the O
transcription B
factor I
NF I
- I
kappa I
B I
. O

Although O
serine O
phosphorylation O
has O
been O
shown O
to O
induce O
ubiquitination O
and O
subsequent O
proteasome O
- O
mediated O
degradation O
of O
I B
kappa I
B I
- I
alpha I
, O
little O
is O
known O
about O
the O
mechanisms O
that O
lead O
to O
release O
of O
active O
NF B
- I
kappa I
B I
in O
T O
cells O
as O
a O
consequence O
of O
tyrosine O
phosphorylation O
of O
I B
kappa I
B I
- I
alpha I
[ O
Imbert O
, O
V O
. O
, O
Rupec O
, O
R O
. O
A O
. O
, O
Livolsi O
, O
A O
. O
, O
Pahl O
, O
H O
. O
L O
. O
, O
Traenckner O
, O
B O
. O
M O
. O
, O
Mueller O
- O
Dieckmann O
, O
C O

Although O
serine O
phosphorylation O
has O
been O
shown O
to O
induce O
ubiquitination O
and O
subsequent O
proteasome O
- O
mediated O
degradation O
of O
I B
kappa I
B I
- I
alpha I
, O
little O
is O
known O
about O
the O
mechanisms O
that O
lead O
to O
release O
of O
active O
NF B
- I
kappa I
B I
in O
T O
cells O
as O
a O
consequence O
of O
tyrosine O
phosphorylation O
of O
I B
kappa I
B I
- I
alpha I
[ O
Imbert O
, O
V O
. O
, O
Rupec O
, O
R O
. O
A O
. O
, O
Livolsi O
, O
A O
. O
, O
Pahl O
, O
H O
. O
L O
. O
, O
Traenckner O
, O
B O
. O
M O
. O
, O
Mueller O
- O
Dieckmann O
, O
C O

Although O
the O
inhibitors O
prevented O
both O
pervanadate O
- O
induced O
phosphorylation O
of O
I B
kappa I
B I
- I
alpha I
on O
Tyr42 O
and O
NF B
- I
kappa I
B I
activation O
, O
we O
observed O
that O
, O
in O
p56 O
( O
lck O
) O
- O
deficient O
Jurkat O
mutants O
, O
NF B
- I
kappa I
B I
could O
still O
associate O
with O
I B
kappa I
B I
- I
alpha I
despite O
phosphorylation O
on O
Tyr42 O
. O

Although O
the O
inhibitors O
prevented O
both O
pervanadate O
- O
induced O
phosphorylation O
of O
I B
kappa I
B I
- I
alpha I
on O
Tyr42 O
and O
NF B
- I
kappa I
B I
activation O
, O
we O
observed O
that O
, O
in O
p56 O
( O
lck O
) O
- O
deficient O
Jurkat O
mutants O
, O
NF B
- I
kappa I
B I
could O
still O
associate O
with O
I B
kappa I
B I
- I
alpha I
despite O
phosphorylation O
on O
Tyr42 O
. O

Finally O
, O
we O
show O
that O
H O
( O
2 O
) O
O O
( O
2 O
) O
, O
which O
stimulates O
p56 B
( I
lck I
) I
and O
ZAP B
- I
70 I
in O
T O
cells O
, O
is O
an O
activator O
of O
NF B
- I
kappa I
B I
through O
tyrosine O
phosphorylation O
of O
I B
kappa I
B I
- I
alpha I
. O

The O
gene O
that O
encodes O
nuclear B
factor I
kappaB I
( I
NF I
- I
kappaB I
) I
essential I
modulator I
( O
or O
NEMO B
, O
also O
known O
as O
IKKgamma B
) O
is O
required O
for O
activation O
of O
the O
transcription B
factor I
NF I
- I
kappaB I
. O

We O
describe O
mutations O
in O
the O
putative B
zinc I
- I
finger I
domain I
of O
NEMO B
that O
result O
in O
an O
X O
- O
linked O
primary O
immunodeficiency O
characterized O
by O
hyper O
- O
IgM O
syndrome O
and O
hypohydrotic O
ectodermal O
dysplasia O
( O
XHM O
- O
ED O
) O
. O

Overall O
, O
the O
phenotype O
observed O
in O
XHM O
- O
ED O
patients O
shows O
that O
the O
putative B
zinc I
- I
finger I
domain I
of O
NEMO B
has O
a O
regulatory O
function O
and O
demonstrates O
the O
definite O
requirement O
of O
CD40 B
- O
mediated O
NF O
- O
kappaB O
activation O
for O
B O
cell O
immunoglobulin O
class O
- O
switching O
. O

IL B
- I
6 I
upregulates O
suppressor B
of I
cytokine I
signaling I
1 I
( O
SOCS1 B
) O
expression O
in O
activated O
CD4 O
+ O
T O
cells O
, O
thereby O
interfering O
with O
signal B
transducer I
and I
activator I
of I
transcription I
1 I
( O
STAT1 B
) O
phosphorylation O
induced O
by O
interferon B
gamma I
( O
IFNgamma B
) O
. O

Interaction O
between O
CCAAT B
/ I
enhancer I
binding I
protein I
and O
cyclic B
AMP I
response I
element I
binding I
protein I
1 I
regulates O
human O
immunodeficiency O
virus O
type O
1 O
transcription O
in O
cells O
of O
the O
monocyte O
/ O
macrophage O
lineage O
. O

Additionally O
, O
sequence O
variation O
at O
C B
/ I
EBP I
site I
I I
, O
which O
lies O
immediately O
upstream O
of O
the O
distal B
nuclear I
factor I
kappa I
B I
site I
and O
immediately O
downstream O
of O
a O
binding O
site O
for O
activating B
transcription I
factor I
( O
ATF B
) O
/ O
cyclic B
AMP I
response I
element I
binding I
protein I
( O
CREB B
) O
, O
has O
been O
shown O
to O
affect O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
activity O
. O

Given O
that O
C B
/ I
EBP I
proteins I
have O
been O
shown O
to O
interact O
with O
many O
other O
transcription B
factors I
including O
members O
of O
the O
ATF B
/ I
CREB I
family I
, O
we O
proceeded O
to O
determine O
whether O
an O
adjacent O
ATF B
/ I
CREB I
binding I
site I
could O
affect O
C B
/ I
EBP I
protein I
binding O
to O
C B
/ I
EBP I
site I
I I
. O

Given O
that O
C B
/ I
EBP I
proteins I
have O
been O
shown O
to O
interact O
with O
many O
other O
transcription B
factors I
including O
members O
of O
the O
ATF B
/ I
CREB I
family I
, O
we O
proceeded O
to O
determine O
whether O
an O
adjacent O
ATF B
/ I
CREB I
binding I
site I
could O
affect O
C B
/ I
EBP I
protein I
binding O
to O
C B
/ I
EBP I
site I
I I
. O

Electrophoretic O
mobility O
shift O
analyses O
indicated O
that O
selected O
ATF B
/ I
CREB I
site I
variants I
assisted O
in O
the O
recruitment O
of O
C B
/ I
EBP I
proteins I
to O
an O
adjacent O
, O
naturally O
occurring O
, O
low O
- O
affinity O
C B
/ I
EBP I
site I
. O

Most O
importantly O
, O
sequence O
variation O
at O
the O
ATF B
/ I
CREB I
binding I
site I
affected O
basal O
LTR B
activity O
as O
well O
as O
LTR B
function O
following O
interleukin B
- I
6 I
stimulation O
, O
a O
treatment O
that O
leads O
to O
increases O
in O
C O
/ O
EBP O
activation O
. O

Thus O
, O
HIV B
- I
1 I
LTR I
ATF B
/ I
CREB I
binding I
site I
sequence O
variation O
may O
modulate O
cellular O
signaling O
at O
the O
viral B
promoter I
through O
the O
C O
/ O
EBP O
pathway O

The O
inhibitory O
effect O
of O
ASA O
on O
IL O
- O
4 O
transcription O
was O
not O
mediated O
by O
decreased O
nuclear O
expression O
of O
the O
known O
salicylate B
target I
nuclear I
factor I
( I
NF I
) I
- I
kappaB I
and O
was O
accompanied O
by O
reduced O
binding O
of O
an O
inducible O
factor O
to O
an O
IL B
- I
4 I
promoter I
region I
upstream O
of O
, O
but O
not O
overlapping O
, O
the O
NF B
of I
activated I
T I
cells I
- I
and I
NF I
- I
kappaB I
- I
binding I
P1 I
element I
. O

METHODS O
: O
Mice O
were O
injected O
intraarticularly O
with O
mBSA B
on O
day O
0 O
and O
subcutaneously O
with O
recombinant B
human I
IL I
- I
1beta I
on O
days O
0 O
- O
2 O
. O

Here O
, O
we O
report O
that O
both O
coding B
and I
noncoding I
sequences I
of O
the O
distal B
5 I
' I
end I
are O
highly O
conserved O
between O
the O
human B
and I
the I
murine I
genes I
, O
and O
the O
distal B
promoter I
is O
responsible O
for O
the O
overwhelming O
majority O
of O
CBFalpha2 O
expression O
in O
murine O
hematopoietic O
stem O
cells O
as O
well O
as O
in O
T O
cells O
. O

The O
distal B
N I
- I
terminal I
isoform I
binds O
to O
functionally O
important O
regulatory B
sites I
from O
known O
target B
genes I
with O
two O
- O
to O
threefold O
higher O
affinity O
than O
the O
proximal B
N I
- I
terminal I
isoform I
. O

The O
distal B
N I
- I
terminal I
isoform I
binds O
to O
functionally O
important O
regulatory B
sites I
from O
known O
target B
genes I
with O
two O
- O
to O
threefold O
higher O
affinity O
than O
the O
proximal B
N I
- I
terminal I
isoform I
. O

The O
mechanism O
responsible O
for O
the O
delayed O
nuclear O
accumulation O
of O
phosphorylated B
STAT3 I
was O
examined O
in O
detail O
, O
focusing O
on O
the O
role O
of O
B B
cell I
- I
derived I
lymphokines I
. O

Transcription B
factor I
AP I
- I
4 I
is O
a O
ligand B
for O
immunoglobulin B
- I
kappa I
promoter I
E I
- I
box I
elements I
. O

In O
the O
present O
study O
we O
show O
that O
the O
ubiquitously O
expressed O
transcription B
factor I
AP I
- I
4 I
, O
and O
not O
E47 B
, O
interacts O
specifically O
with O
the O
kappa B
promoter I
E I
- I
boxes I
when O
tested O
in O
electrophoretic O
mobility O
- O
shift O
assays O
using O
nuclear O
extracts O
derived O
from O
human O
and O
murine O
B O
- O
cell O
lines O
. O

In O
the O
present O
study O
we O
show O
that O
the O
ubiquitously O
expressed O
transcription B
factor I
AP I
- I
4 I
, O
and O
not O
E47 B
, O
interacts O
specifically O
with O
the O
kappa B
promoter I
E I
- I
boxes I
when O
tested O
in O
electrophoretic O
mobility O
- O
shift O
assays O
using O
nuclear O
extracts O
derived O
from O
human O
and O
murine O
B O
- O
cell O
lines O
. O

Based O
on O
these O
data O
, O
and O
the O
conservation O
of O
the O
5 B
' I
- I
CAGCTG I
- I
3 I
' I
motif I
among O
human B
and I
murine I
kappa I
promoters I
, O
we O
propose O
that O
AP B
- I
4 I
is O
the O
major B
ligand I
for O
Ig B
- I
kappa I
promoter I
E I
- I
boxes I
. O

To O
study O
B O
cell O
- O
specific O
changes O
that O
occur O
during O
the O
aging O
process O
, O
we O
investigated O
expression O
patterns O
of O
Pax B
- I
5a I
and I
5d I
in O
mature O
B O
cells O
of O
young O
and O
aged O
mice O
. O

In O
contrast O
, O
a O
significant O
reduction O
in O
the O
DNA O
binding O
activity O
of O
Pax B
- I
5a I
but O
not O
Pax B
- I
5d I
protein O
was O
observed O
in O
aged O
B O
cells O
in O
vitro O
, O
while O
Western O
blot O
analyses O
showed O
that O
similar O
levels O
of O
Pax B
- I
5a I
and I
5d I
proteins O
were O
present O
in O
both O
age O
groups O
. O

The O
observed O
decrease O
in O
Pax B
- I
5a I
binding O
activity O
correlated O
with O
changes O
in O
expression O
of O
two O
Pax B
- I
5 I
target I
genes I
in O
aged O
B O
cells O
. O

Specific O
nongenomic O
effects O
occur O
within O
a O
few O
minutes O
and O
are O
mediated O
by O
steroid B
- I
selective I
membrane I
receptors I
. O

High O
glucose O
- O
induced O
intercellular B
adhesion I
molecule I
- I
1 I
( O
ICAM B
- I
1 I
) O
expression O
through O
an O
osmotic O
effect O
in O
rat O
mesangial O
cells O
is O
PKC O
- O
NF O
- O
kappa O
B O
- O
dependent O
. O

We O
also O
measured O
the O
effect O
of O
high O
glucose O
on O
the O
expression O
of O
intercellular B
adhesion I
molecule I
- I
1 I
and O
vascular B
adhesion I
molecule I
- I
1 I
by O
flow O
cytometry O
and O
semiquantitative O
RT O
- O
PCR O
in O
mesangial O
cells O
and O
the O
adhesion O
of O
leukocytes O
to O
mesangial O
cells O
. O

We O
also O
measured O
the O
effect O
of O
high O
glucose O
on O
the O
expression O
of O
intercellular B
adhesion I
molecule I
- I
1 I
and O
vascular B
adhesion I
molecule I
- I
1 I
by O
flow O
cytometry O
and O
semiquantitative O
RT O
- O
PCR O
in O
mesangial O
cells O
and O
the O
adhesion O
of O
leukocytes O
to O
mesangial O
cells O
. O

Cells O
exposed O
to O
high O
- O
glucose O
( O
15 O
, O
30 O
, O
or O
60 O
mmol O
/ O
l O
) O
or O
osmotic O
agents O
( O
L O
- O
glucose O
, O
raffinose O
and O
mannitol O
) O
showed O
that O
intercellular B
adhesion I
molecule I
- I
1 I
expression O
began O
to O
increase O
after O
24 O
h O
, O
reached O
its O
maximum O
at O
24 O
and O
48 O
h O
and O
gradually O
decreased O
afterwards O
. O

Up O
- O
regulation O
of O
ICAM B
- I
1 I
protein O
and O
mRNA O
was O
also O
found O
in O
IL B
- I
1 I
- I
beta I
and O
TNF B
- I
alpha I
- O
stimulated O
mesangial O
cells O
. O

Neither O
vascular B
adhesion I
molecule I
- I
1 I
protein O
nor O
mRNA O
expression O
was O
, O
however O
, O
affected O
by O
high O
glucose O
and O
high O
mannitol O
. O

Notably O
, O
the O
protein O
kinase O
C O
inhibitors O
calphostin O
C O
and O
staurosporine O
reduced O
high O
glucose O
- O
or O
high O
mannitol O
- O
induced O
intercellular B
adhesion I
molecule I
- I
1 I
mRNA O
expression O
and O
high O
glucose O
- O
induced O
proliferation O
. O

Furthermore O
, O
the O
NF O
- O
kappa O
B O
inhibitor O
N O
- O
tosyl O
- O
L O
- O
phenylalanine O
chloromethyl O
ketone O
reduced O
high O
glucose O
- O
or O
high O
mannitol O
- O
induced O
intercellular B
adhesion I
molecule I
- I
1 I
mRNA O
expression O
and O
high O
glucose O
- O
induced O
proliferation O
. O

Functional O
blocking O
of O
intercellular B
adhesion I
molecule I
- I
1 I
on O
mesangial O
cells O
with O
rat B
intercellular I
adhesion I
molecule I
- I
1 I
monoclonal I
antibody I
, O
calphostin O
C O
, O
staurosporine O
, O
or O
N O
- O
tosyl O
- O
L O
- O
phenylalanine O
chloromethyl O
ketone O
significantly O
inhibited O
high O
glucose O
- O
or O
high O
mannitol O
- O
induced O
increase O
in O
leukocyte O
adhesion O
( O
p O
< O
< O
0 O
. O
05 O
) O
. O

CONCLUSION O
/ O
INTERPRETATION O
: O
These O
results O
suggest O
that O
high O
glucose O
can O
upregulate O
intercellular B
adhesion I
molecule I
- I
1 I
protein O
and O
mRNA O
expression O
but O
not O
vascular O
adhesion O
molecule O
- O
1 O
expression O
in O
mesangial O
cells O
and O
promote O
leukocyte O
adhesion O
through O
up O
- O
regulation O
of O
intercellular B
adhesion I
molecule I
- I
1 I
through O
osmotic O
effect O
, O
possibly O
depending O
on O
the O
protein B
kinase I
C I
nuclear B
factor I
- I
kappa I
B I
( O
PKC B
- O
NF B
- I
kappa I
B I
) O
pathway O
. O

CONCLUSION O
/ O
INTERPRETATION O
: O
These O
results O
suggest O
that O
high O
glucose O
can O
upregulate O
intercellular B
adhesion I
molecule I
- I
1 I
protein O
and O
mRNA O
expression O
but O
not O
vascular O
adhesion O
molecule O
- O
1 O
expression O
in O
mesangial O
cells O
and O
promote O
leukocyte O
adhesion O
through O
up O
- O
regulation O
of O
intercellular B
adhesion I
molecule I
- I
1 I
through O
osmotic O
effect O
, O
possibly O
depending O
on O
the O
protein B
kinase I
C I
nuclear B
factor I
- I
kappa I
B I
( O
PKC B
- O
NF B
- I
kappa I
B I
) O
pathway O
. O

CONCLUSION O
/ O
INTERPRETATION O
: O
These O
results O
suggest O
that O
high O
glucose O
can O
upregulate O
intercellular B
adhesion I
molecule I
- I
1 I
protein O
and O
mRNA O
expression O
but O
not O
vascular O
adhesion O
molecule O
- O
1 O
expression O
in O
mesangial O
cells O
and O
promote O
leukocyte O
adhesion O
through O
up O
- O
regulation O
of O
intercellular B
adhesion I
molecule I
- I
1 I
through O
osmotic O
effect O
, O
possibly O
depending O
on O
the O
protein B
kinase I
C I
nuclear B
factor I
- I
kappa I
B I
( O
PKC B
- O
NF B
- I
kappa I
B I
) O
pathway O
. O

Combined O
corticosteroid O
/ O
granulocyte B
colony I
- I
stimulating I
factor I
( O
G B
- I
CSF I
) O
therapy O
in O
the O
treatment O
of O
severe O
congenital O
neutropenia O
unresponsive O
to O
G B
- I
CSF I
: O
Activated O
glucocorticoid B
receptors I
synergize O
with O
G B
- I
CSF I
signals O
. O

More O
than O
90 O
% O
of O
patients O
with O
severe O
congenital O
neutropenia O
( O
SCN O
) O
respond O
to O
granulocyte B
colony I
- I
stimulating I
factor I
( O
G B
- I
CSF I
) O
therapy O
. O

Interestingly O
, O
the O
retinoid O
also O
inhibited O
in O
FCS O
- O
stimulated O
cells O
the O
protein O
expression O
of O
two O
mesangial B
adhesion I
molecules I
, O
fibronectin B
and O
osteopontin B
, O
but O
it O
did O
not O
modify O
the O
protein O
expression O
of O
intercellular B
adhesion I
molecule I
- I
1 I
and O
vascular B
adhesion I
molecule I
- I
1 I
. O

Interestingly O
, O
the O
retinoid O
also O
inhibited O
in O
FCS O
- O
stimulated O
cells O
the O
protein O
expression O
of O
two O
mesangial B
adhesion I
molecules I
, O
fibronectin B
and O
osteopontin B
, O
but O
it O
did O
not O
modify O
the O
protein O
expression O
of O
intercellular B
adhesion I
molecule I
- I
1 I
and O
vascular B
adhesion I
molecule I
- I
1 I
. O

The O
murine B
IL I
- I
2 I
promoter I
contains O
distal B
regulatory I
elements I
responsive O
to O
the O
Ah B
receptor I
, O
a O
member O
of O
the O
evolutionarily O
conserved O
bHLH B
- I
PAS I
transcription I
factor I
family I
. O

Binding O
motifs O
for O
the O
liganded B
AHR I
can O
be O
identified O
in O
the O
distal B
region I
- I
1300 I
to I
- I
800 I
of O
the O
mouse B
IL I
- I
2 I
promoter I
. O

Thus O
, O
the O
IL B
- I
2 I
promoter I
region I
contains O
novel O
distal B
regulatory I
elements I
that O
can O
be O
addressed O
by O
the O
AHR B
to O
induce O
IL B
- I
2 I
and O
can O
cooperate O
with O
the O
proximal B
promoter I

In O
the O
absence O
of O
Lyn B
, O
receptor B
- I
Syk I
complexes I
at O
the O
plasma O
membrane O
are O
long O
lived O
, O
and O
the O
receptor O
- O
mediated O
activation O
of O
the O
NF B
- I
AT I
transcription I
factor I
is O
enhanced O
. O

Renal O
interstitial O
fibrosis O
is O
reduced O
in O
angiotensin B
II I
type I
1a I
receptor I
- O
deficient O
mice O
. O

The O
relative O
volume O
of O
the O
tubulointerstitium O
was O
measured O
by O
an O
image O
analyzer O
; O
deposition O
of O
collagen B
types I
III I
and I
IV I
and O
monocyte O
/ O
macrophage O
infiltration O
were O
histologically O
examined O
using O
specific B
antibodies I
. O

Also O
determined O
were O
the O
mRNA O
levels O
of O
transforming B
growth I
factor I
- I
beta I
by O
Northern O
blot O
analysis O
. O

UUO O
in O
wild O
mice O
resulted O
in O
a O
marked O
expansion O
of O
relative O
volume O
of O
the O
tubulointerstitium O
, O
together O
with O
increased O
deposition O
of O
collagen B
types I
III I
and I
IV I
and O
number O
of O
infiltrated O
monocytes O
/ O
macrophages O
in O
the O
interstitium O
, O
relative O
to O
sham O
- O
operated O
mice O
. O

The O
mRNA O
level O
of O
transforming B
growth I
factor I
- I
beta I
was O
significantly O
higher O
in O
the O
OBK O
of O
wild O
mice O
with O
UUO O
compared O
with O
sham O
- O
operated O
mice O
. O

MHC B
tetramers I
, O
which O
constitute O
a O
labeled B
MHC I
- I
peptide I
ligand I
suitable O
for O
binding O
to O
the O
Ag B
- I
specific I
receptor I
on O
T O
cells O
, O
provide O
a O
novel O
approach O
for O
the O
detection O
and O
characterization O
of O
such O
rare O
cells O
. O

Peptides O
representing O
potential O
epitope B
regions I
of O
the O
VP16 B
protein I
from O
HSV O
- O
2 O
were O
loaded O
onto O
recombinant B
DQ0602 I
molecules I
to O
generate O
a O
panel O
of O
Ag B
- I
specific I
DQ0602 I
tetramers I
. O

As O
immunoglobulin O
transcription O
is O
mainly O
regulated O
by O
the O
B B
- I
cell I
transcription I
factors I
Oct2 B
and O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
, O
we O
analyzed O
35 O
cases O
of O
LPHD O
, O
32 O
cases O
of O
cHD O
, O
and O
2 O
Hodgkin O
disease O
cell O
lines O
for O
the O
expression O
of O
these O
transcription B
factors I
and O
also O
in O
parallel O
for O
immunoglobulin O
expression O
. O

Recently O
, O
members O
of O
the O
NF B
- I
kappaB I
family I
, O
including O
p65 B
( I
Rel I
A I
) I
, O
have O
been O
implicated O
in O
promoting O
survival O
of O
various O
hematopoeitic O
neoplasms O
, O
including O
T O
cell O
malignancies O
such O
as O
adult O
T O
cell O
leukemia O
- O
lymphoma O
. O

Paraffin O
- O
embedded O
tissues O
from O
23 O
cutaneous O
lesions O
and O
a O
single O
lymph O
node O
biopsy O
from O
patients O
diagnosed O
with O
MF O
were O
evaluated O
for O
p65 O
( O
Rel O
A O
) O
expression O
by O
using O
a O
monoclonal B
mouse I
antibody I
that O
detects O
the O
activated O
form O
of O
p65 B
( I
Rel I
A I
) I
. O

Nuclear O
expression O
of O
p65 B
( I
Rel I
A I
) I
before O
and O
after O
treatment O
with O
the O
various O
inhibitory O
compounds O
was O
measured O
by O
immunofluorescence O
staining O
in O
each O
CTCL O
cell O
line O
. O

Human O
T O
- O
cell O
leukemia O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
Tax B
protein I
induces O
the O
expression O
of O
various O
family O
members O
of O
the O
transcription B
factor I
AP I
- I
1 I
, O
such O
as O
c B
- I
Jun I
, O
JunD B
, O
c B
- I
Fos I
, O
and O
Fra B
- I
1 I
, O
at O
the O
level O
of O
RNA O
expression O
in O
T O
cells O
. O

Soluble O
mediators O
in O
SF O
of O
subjects O
with O
RA O
and O
OA O
can O
therefore O
modulate O
binding O
of O
nuclear B
proteins I
to O
the O
NF B
- I
kappaB I
binding I
site I
in O
macrophages O
and O
may O
play O
a O
role O
in O
inflammatory O
gene O
expression O
in O
arthritis O
. O

Activated B
STAT3 I
was O
shown O
to O
bind O
an O
SIE B
- I
related I
element I
in O
the O
murine B
mcl I
- I
1 I
promoter I
. O

Decreased O
immediate O
inflammatory B
gene I
induction O
in O
activating B
transcription I
factor I
- I
2 I
mutant O
mice O
. O

To O
better O
define O
the O
role O
of O
ATF B
- I
2 I
in O
inflammation O
, O
adult O
mice O
expressing O
small O
amounts O
of O
a O
mutant B
ATF I
- I
2 I
protein I
were O
challenged O
with O
lipopolysaccharide O
( O
LPS O
) O
, O
anti B
- I
CD3 I
antibody I
or O
virus O
. O

Within O
3 O
h O
of O
challenge O
by O
LPS O
, O
ATF O
- O
2 O
mutant O
mice O
had O
decreased O
induction O
of O
the O
adhesion B
molecules I
E B
- I
selectin I
, O
P B
- I
selectin I
and O
VCAM B
- I
1 I
as O
well O
as O
the O
cytokines B
tumor B
necrosis I
factor I
- I
alpha I
, O
IL B
- I
1beta I
and O
IL B
- I
6 I
compared O
with O
control O
mice O
. O

Blockade O
of O
LIGHT B
by O
its O
soluble B
receptors I
, O
lymphotoxin B
beta I
receptor I
- I
Ig I
or O
HVEM B
- I
Ig I
, O
inhibits O
the O
induction O
of O
DC O
- O
mediated O
primary O
allogeneic O
T O
cell O
response O
. O

The O
expression O
of O
almost O
all O
of O
the O
cytokines B
produced O
by O
eosinophils O
, O
including O
the O
proallergic B
cytokine I
IL I
- I
4 I
, O
is O
now O
known O
to O
be O
regulated O
at O
the O
level O
of O
transcription O
by O
members O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
family O
of O
transcription O
factors O
. O

To O
delineate O
the O
mechanisms O
of O
transcriptional O
activation O
, O
we O
recently O
cloned O
the O
5 B
' I
- I
flanking I
region I
of O
the O
MIP B
- I
2 I
gene I
. O

The O
promotor B
region I
contains O
consensus B
binding I
sites I
for O
transcription B
factor I
nuclear I
factor I
kappaB I
( O
NF B
- I
kappaB I
) O
and O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
. O

p65 B
( I
Rel I
A I
) I
and O
p50 B
protein I
appears O
to O
be O
involved O
in O
MIP O
- O
2 O
NF B
- I
kappaB I
binding O
. O

Apoptosis O
induction O
could O
be O
abrogated O
mainly O
by O
antibodies B
against O
tumour B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
and O
, O
to O
a O
lesser O
extent O
, O
by O
antibodies B
against O
IFN B
- I
gamma I
. O

Bone O
resorption O
is O
regulated O
by O
the O
immune O
system O
, O
where O
T O
- O
cell O
expression O
of O
RANKL B
( O
receptor B
activator I
of I
nuclear I
factor I
( I
NF I
) I
- I
kappaB I
ligand I
) O
, O
a O
member O
of O
the O
tumour B
- I
necrosis I
factor I
family I
that O
is O
essential O
for O
osteoclastogenesis O
, O
may O
contribute O
to O
pathological O
conditions O
, O
such O
as O
autoimmune O
arthritis O
. O

Stromal B
- I
derived I
factor I
1 I
and O
thrombopoietin B
regulate O
distinct O
aspects O
of O
human O
megakaryopoiesis O
. O

The O
role O
of O
the O
chemokine B
binding O
stromal B
- I
derived I
factor I
1 I
( O
SDF B
- I
1 I
) O
in O
normal O
human O
megakaryopoiesis O
at O
the O
cellular O
and O
molecular O
levels O
and O
its O
comparison O
with O
that O
of O
thrombopoietin B
( O
TPO B
) O
have O
not O
been O
determined O
. O

We O
found O
that O
adhesion O
of O
unstimulated O
T O
cell O
i O
) O
involved O
beta1 O
, O
but O
not O
beta4 O
integrin O
functions O
at O
the O
surface O
ii O
) O
induced O
the O
clustering O
of O
alpha3beta1 B
, O
but O
not O
alpha2beta1 B
heterodimers I
at O
the O
TEC O
surface O
and O
iii O
) O
up O
- O
regulated O
the O
nuclear O
binding O
activity O
of O
NF B
- I
kappaB I
transcription I
factor I
and O
the O
IL O
- O
6 O
secretion O
. O

The O
hsp70 B
co I
- I
chaperone I
Hip I
has O
been O
recovered O
in O
receptor B
. I
hsp90 I
heterocomplexes I
at O
an O
intermediate O
stage O
of O
assembly O
in O
reticulocyte O
lysate O
, O
and O
Hip B
is O
also O
thought O
to O
be O
an O
intrinsic O
component O
of O
the O
assembly O
machinery O
. O

We O
previously O
showed O
that O
Tax B
induces O
the O
expression O
of O
various O
family O
members O
of O
the O
transcription B
factor I
AP I
- I
1 I
such O
as O
c B
- I
Jun I
, O
JunD B
, O
c B
- I
Fos I
, O
and O
Fra B
- I
1 I
at O
the O
mRNA O
level O
in O
T O
cells O
. O

Moreover O
, O
the O
differentiation O
status O
of O
these O
Raf O
- O
responsive O
cells O
was O
more O
immature O
upon O
Raf O
activation O
as O
culture O
with O
the O
differentiation O
- O
inducing O
agent O
phorbol O
12 O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
and O
beta O
- O
estradiol O
resulted O
in O
decreased O
levels O
of O
the O
CD11b B
and I
CD18 I
integrin I
molecules I
on O
the O
cell O
surface O
. O

Our O
data O
also O
show O
that O
cAMP O
causes O
increased O
phosphorylation O
of O
the O
transcription B
factor I
GATA I
- I
3 I
, O
which O
we O
have O
shown O
is O
a O
critical O
regulator O
of O
Th2 O
cytokine O
gene O
expression O
and O
, O
in O
turn O
, O
of O
airway O
inflammation O
in O
mice O
. O

IL B
- I
13 I
receptor I
alpha I
chain I
1 I
( O
IL B
- I
13R I
alpha I
1 I
) O
is O
necessary O
for O
binding O
to O
IL B
- I
13 I
, O
and O
the O
heterodimer O
composed O
of O
IL B
- I
13R I
alpha I
1 I
and O
IL B
- I
4R I
alpha I
chain I
transduces O
IL B
- I
13 I
and O
IL B
- I
4 I
signals O
; O
however O
, O
the O
functional O
mapping O
of O
the O
intracellular B
domain I
of O
IL B
- I
13R I
alpha I
1 I
is O
not O
fully O
understood O
. O

IL B
- I
13 I
receptor I
alpha I
chain I
1 I
( O
IL B
- I
13R I
alpha I
1 I
) O
is O
necessary O
for O
binding O
to O
IL B
- I
13 I
, O
and O
the O
heterodimer O
composed O
of O
IL B
- I
13R I
alpha I
1 I
and O
IL B
- I
4R I
alpha I
chain I
transduces O
IL B
- I
13 I
and O
IL B
- I
4 I
signals O
; O
however O
, O
the O
functional O
mapping O
of O
the O
intracellular B
domain I
of O
IL B
- I
13R I
alpha I
1 I
is O
not O
fully O
understood O
. O

IL B
- I
13 I
receptor I
alpha I
chain I
1 I
( O
IL B
- I
13R I
alpha I
1 I
) O
is O
necessary O
for O
binding O
to O
IL B
- I
13 I
, O
and O
the O
heterodimer O
composed O
of O
IL B
- I
13R I
alpha I
1 I
and O
IL B
- I
4R I
alpha I
chain I
transduces O
IL B
- I
13 I
and O
IL B
- I
4 I
signals O
; O
however O
, O
the O
functional O
mapping O
of O
the O
intracellular B
domain I
of O
IL B
- I
13R I
alpha I
1 I
is O
not O
fully O
understood O
. O

IL B
- I
13 I
receptor I
alpha I
chain I
1 I
( O
IL B
- I
13R I
alpha I
1 I
) O
is O
necessary O
for O
binding O
to O
IL B
- I
13 I
, O
and O
the O
heterodimer O
composed O
of O
IL B
- I
13R I
alpha I
1 I
and O
IL B
- I
4R I
alpha I
chain I
transduces O
IL B
- I
13 I
and O
IL B
- I
4 I
signals O
; O
however O
, O
the O
functional O
mapping O
of O
the O
intracellular B
domain I
of O
IL B
- I
13R I
alpha I
1 I
is O
not O
fully O
understood O
. O

In O
this O
study O
, O
we O
constructed O
wild O
and O
mutated O
types O
of O
human B
IL I
- I
13R I
alpha I
1 I
, O
and O
analyzed O
IL B
- I
4 I
and O
IL B
- I
13 I
signals O
using O
an O
IL B
- I
13R I
alpha I
1 I
- O
transfected O
human O
B O
cell O
line O
. O

Expression O
of O
IL B
- I
13R I
alpha I
1 I
evoked O
STAT3 B
activation O
by O
IL B
- I
4 I
and O
IL B
- I
13 I
, O
and O
in O
stimulated O
human O
B O
cells O
, O
on O
which O
IL B
- I
13R I
alpha I
1 I
was O
highly O
expressed O
, O
IL B
- I
4 I
and O
IL B
- I
13 I
induced O
STAT3 B
activation O
. O

Expression O
of O
IL B
- I
13R I
alpha I
1 I
evoked O
STAT3 B
activation O
by O
IL B
- I
4 I
and O
IL B
- I
13 I
, O
and O
in O
stimulated O
human O
B O
cells O
, O
on O
which O
IL B
- I
13R I
alpha I
1 I
was O
highly O
expressed O
, O
IL B
- I
4 I
and O
IL B
- I
13 I
induced O
STAT3 B
activation O
. O

Furthermore O
, O
we O
found O
that O
the O
Box1 B
region I
and O
the O
C B
- I
terminal I
tail I
of O
IL B
- I
13R I
alpha I
1 I
were O
critical O
for O
binding O
to O
Tyk2 B
, O
and O
activation O
of O
Jak1 B
, O
Tyk2 B
, O
the O
insulin B
receptor I
substrate I
- I
1 I
and O
STAT6 B
respectively O
. O

Furthermore O
, O
we O
found O
that O
the O
Box1 B
region I
and O
the O
C B
- I
terminal I
tail I
of O
IL B
- I
13R I
alpha I
1 I
were O
critical O
for O
binding O
to O
Tyk2 B
, O
and O
activation O
of O
Jak1 B
, O
Tyk2 B
, O
the O
insulin B
receptor I
substrate I
- I
1 I
and O
STAT6 B
respectively O
. O

These O
results O
suggest O
that O
STAT3 B
activation O
is O
involved O
with O
IL B
- I
4 I
and O
IL B
- I
13 I
signals O
in O
human O
B O
cells O
along O
with O
the O
activation O
of O
STAT6 B
, O
and O
that O
there O
is O
a O
unique O
sequence O
in O
IL B
- I
13R I
alpha I
1 I
to O
activate O
STAT3 B
. O

The O
Epstein B
- I
Barr I
virus I
promoter I
initiating O
B O
- O
cell O
transformation O
is O
activated O
by O
RFX B
proteins I
and O
the O
B B
- I
cell I
- I
specific I
activator I
protein I
BSAP I
/ I
Pax5 I
. O

To O
investigate O
the O
mechanism O
of O
such O
inhibition O
, O
the O
role O
of O
two O
mitogen O
- O
activated O
protein O
kinase O
pathways O
, O
c B
- I
Jun I
N I
- I
terminal I
kinase I
( O
JNK B
) O
and O
extracellular B
signal I
- I
regulated I
kinase I
( O
ERK B
) O
, O
in O
modulating O
RXRE O
- O
dependent O
transcription O
, O
was O
explored O
. O

OBJECTIVE O
: O
The O
transcription B
factor I
NF I
- I
E2 I
, O
a O
heterodimeric B
protein I
complex I
composed O
of O
p45 B
and O
small O
Maf B
family I
proteins I
, O
is O
considered O
crucial O
for O
the O
proper O
differentiation O
of O
erythrocytes O
and O
megakaryocytes O
in O
vivo O
. O

The O
time O
course O
of O
heme B
oxygenase I
- I
1 I
and I
- I
2 I
, O
cytokine B
- I
induced I
neutrophil I
chemoattractant I
- I
1 I
, O
and O
intercellular B
adhesion I
molecule I
- I
1 I
was O
studied O
by O
Northern O
analysis O
. O

RESULTS O
: O
Acetaminophen O
caused O
a O
moderate O
sinusoidal O
perfusion O
failure O
( O
- O
15 O
% O
) O
and O
infiltration O
of O
neutrophils O
along O
with O
activation O
of O
nuclear B
factor I
- I
kappaB I
and O
intercellular B
adhesion I
molecule I
- I
1 I
and O
cytokine B
- I
induced I
neutrophil I
chemoattractant I
- I
1 I
mRNAs O
. O

CONCLUSIONS O
: O
The O
inflammatory O
response O
associated O
with O
acetaminophen O
hepatotoxicity O
is O
modulated O
by O
the O
parallel O
induction O
of O
the O
heme B
oxygenase I
- I
1 I
gene I
. O

Tumor B
necrosis I
factor I
- I
alpha I
- O
induced O
proliferation O
requires O
synthesis O
of O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
. O

OBJECTIVE O
: O
Tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
induces O
a O
variety O
of O
cellular O
responses O
, O
some O
of O
them O
being O
at O
least O
seemingly O
contradictory O
. O

RESULTS O
: O
All O
cell O
lines O
tested O
expressed O
TNF B
- I
alpha I
receptors I
I I
and I
II I
and O
responded O
to O
TNF B
- I
alpha I
by O
upregulation O
of O
intercellular B
adhesion I
molecule I
- I
1 I
. O

The O
Src B
- I
like I
protein I
- I
tyrosine I
kinase I
Fyn B
is O
associated O
with O
T B
- I
cell I
antigen I
receptor I
. O

Transient O
expression O
of O
actively O
mutated O
Fyn B
, O
having O
Phe O
- O
528 O
instead O
of O
Tyr O
- O
528 O
or O
Thr O
- O
338 O
instead O
of O
Ile O
- O
338 O
, O
in O
Jurkat O
T O
- O
cells O
stimulated B
the I
serum I
response I
element I
( O
SRE B
) O
, O
12 B
- I
O I
- I
tetradecanoyl I
- I
phorbol I
- I
13 I
- I
acetate I
response I
element I
, O
cyclic B
AMP I
response I
element I
, O
and O
c B
- I
fos I
promoter I
. O

Furthermore O
, O
normal B
and I
active I
Fyn I
stimulated O
transcription O
from O
the O
IL B
- I
2 I
gene I
promoter I
when O
transfected O
cells O
were O
stimulated O
by O
concanavalin B
A I
plus O
12 O
- O
O O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
. O

A O
novel O
NF B
- I
kappa I
B I
complex I
containing O
p65 B
homodimers I
: O
implications O
for O
transcriptional O
control O
at O
the O
level O
of O
subunit O
dimerization O
. O

We O
compared O
the O
expression O
of O
Egr B
- I
1 I
during O
B O
cell O
stimulation O
with O
Fab B
' I
2 I
and O
IgG B
anti I
- I
immunoglobulin I
( O
anti B
- I
Ig I
) O
, O
since O
it O
is O
known O
that O
Fab B
' I
2 I
anti I
- I
Ig I
is O
mitogenic O
while O
IgG B
anti I
- I
Ig I
is O
not O
, O
owing O
to O
a O
dominant O
inhibitory O
effect O
of O
crosslinking O
the O
B B
cell I
Fc I
gamma I
RII I
to O
membrane B
Ig I
. O

Differences O
in O
expression O
of O
transcription B
factor I
AP I
- I
1 I
in O
human O
promyelocytic O
HL O
- O
60 O
cells O
during O
differentiation O
towards O
macrophages O
versus O
granulocytes O
. O

The O
commitment O
stage O
towards O
PMA O
- O
induced O
macrophage O
differentiation O
was O
associated O
with O
increases O
in O
jun O
B O
and O
c O
- O
fos O
mRNA O
levels O
, O
as O
well O
as O
with O
an O
increase O
in O
the O
binding O
activity O
of O
transcription B
factor I
AP I
- I
1 I
. O

For O
cytoplasmic B
glucocorticoid I
- I
receptor I
complexes I
to O
enter O
and O
accumulate O
in O
the O
nucleus O
a O
temperature O
- O
dependent O
event O
, O
' O
activation O
' O
is O
required O
. O

We O
describe O
a O
novel O
and O
potentially O
important O
mechanism O
of O
nitric O
oxide O
signaling O
- O
through O
direct O
activation O
of O
guanine B
nucleotide I
- I
binding I
proteins I
( O
G B
proteins I
) O
. O

We O
have O
previously O
shown O
that O
a O
fragment O
containing O
bp B
- I
95 I
to I
+ I
27 I
of O
the O
mouse B
GM I
- I
CSF I
promoter I
can O
confer O
inducibility O
to O
reporter B
genes I
in O
the O
human O
Jurkat O
T O
- O
cell O
line O
. O

As O
an O
initial O
step O
towards O
understanding O
the O
molecular O
basis O
for O
tissue O
- O
specific O
expression O
of O
this O
gene O
, O
we O
surveyed O
the O
surrounding O
chromatin O
structure O
for O
potential O
cis B
- I
acting I
regulatory I
regions I
by O
DNase B
I I
hypersensitivity O
mapping O
and O
found O
four O
hypersensitive O
sites O
, O
three O
of O
which O
were O
T O
cell O
restricted O
. O

Taken O
together O
, O
these O
results O
suggest O
that O
the O
human B
CD8 I
alpha I
gene I
is O
regulated O
by O
the O
interaction O
of O
multiple O
T B
- I
cell I
nuclear I
proteins I
with O
a O
transcriptional O
enhancer O
located O
in O
the O
last O
intron B
of O
the O
gene O
. O

Molecular O
regulation O
of O
the O
human B
IL I
- I
3 I
gene I
: O
inducible O
T O
cell O
- O
restricted O
expression O
requires O
intact O
AP B
- I
1 I
and I
Elf I
- I
1 I
nuclear I
protein I
binding I
sites I
. O

Studies O
to O
date O
have O
identified O
elements O
5 O
' O
to O
the O
IL B
- I
3 I
coding I
sequences I
that O
regulate O
its O
transcription O
, O
but O
the O
sequences O
that O
confer O
T O
cell O
- O
specific O
expression O
remain O
to O
be O
clearly O
defined O
. O

Deletion O
analysis O
revealed O
that O
T O
cell O
specificity O
was O
conferred O
by O
a O
49 B
- I
bp I
fragment I
( O
bp B
- I
319 I
to I
- I
270 I
) O
that O
included O
a O
potential B
binding I
site I
for O
AP B
- I
1 I
transcription I
factors I
6 O
bp O
upstream O
of O
a O
binding B
site I
for I
Elf I
- I
1 I
, O
a O
member O
of O
the O
Ets B
family I
of O
transcription B
factors I
. O

We O
conclude O
that O
expression O
of O
the O
human B
IL I
- I
3 I
gene I
requires O
the O
AP B
- I
1 I
and I
Elf I
- I
1 I
binding I
sites I
; O
however O
, O
unlike O
other O
previously O
characterized O
cytokine B
genes I
such O
as O
IL B
- I
2 I
, O
the O
AP B
- I
1 I
and I
Elf I
- I
1 I
factors I
can O
bind O
independently O
in O
the O
IL B
- I
3 I
gene I
. O

We O
analyzed O
the O
5 B
' I
transcription I
control I
sequences I
of O
the O
human B
CD4 I
gene I
. O

The O
leukocyte O
migration O
inhibition O
response O
to O
certain O
breast B
cancer I
- I
related I
antigens I
( O
MCF B
- I
7 I
and O
MuMTV B
) O
: O
their O
potential O
as O
discriminants O
. O

Treatment O
of O
Mono O
Mac O
6 O
cells O
with O
pyrrolidine O
- O
dithiocarbamate O
( O
PDTC O
) O
at O
300 O
microM O
will O
block O
the O
LPS B
- I
induced I
complex I
I I
almost O
completely O
and O
will O
reduce O
complex B
II I
to O
the O
constitutive O
level O
. O

Northern O
blot O
analysis O
demonstrates O
that O
PDTC O
treatment O
will O
strongly O
reduce O
LPS B
- I
induced I
TNF I
transcripts I
. O

Here O
it O
is O
shown O
that O
ZEBRA B
also O
behaves O
as O
a O
sequence B
- I
specific I
transcriptional I
activator I
in O
Saccharomyces O
cerevisiae O
. O

The O
amino B
- I
terminal I
region I
of O
ZEBRA B
( O
aa B
1 I
to I
98 I
) O
was O
required O
for O
activation O
both O
in O
S O
. O
cerevisiae O
and O
in O
human O
B O
cells O
; O
deletion O
of O
the O
carboxy B
- I
terminal I
18 I
aa I
also O
significantly O
reduced O
activation O
in O
both O
cell O
types O
. O

For O
example O
, O
deletion O
of O
ZEBRA B
aa I
26 I
to I
51 I
impaired O
activation O
to O
a O
great O
extent O
in O
B O
cells O
but O
had O
little O
or O
no O
effect O
in O
S O
. O
cerevisiae O
. O

In O
the O
primitive O
erythroid O
lineage O
, O
transcription O
of O
the O
embryonic B
epsilon I
- I
globin I
gene I
parallels O
GATA O
- O
1 O
expression O
while O
the O
switch O
to O
beta O
- O
globin O
transcription O
in O
definitive O
erythroid O
cells O
is O
directly O
preceded O
by O
a O
pronounced O
increase O
in O
GATA B
- I
3 I
accumulation O
. O

Electrophoretic O
mobility O
shift O
assays O
using O
a O
DNA O
oligomer O
containing O
the O
NFIL B
- I
2B I
binding I
site I
indicated O
that O
IL B
- I
4 I
inhibited O
the O
NFIL B
- I
2B I
complex I
and O
that O
the O
NFIL B
- I
2B I
DNA I
binding I
factor I
is O
distinct O
from O
AP B
- I
1 O
. O

Both O
PTK O
inhibitors O
also O
reduced O
the O
LPS O
activation O
of O
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
which O
is O
a O
transcription B
factor I
involved O
in O
the O
expression O
of O
cytokine B
genes I
such O
as O
IL B
- I
6 I
and O
TNF B
- I
alpha I
. O

It O
has O
been O
shown O
in O
vitro O
that O
dissociation O
of O
I B
kappa I
B I
alpha I
from O
these O
complexes O
results O
in O
active B
NF I
- I
kappa I
B I
. O

In O
this O
report O
we O
show O
that O
lipopolysaccharide O
( O
LPS O
) O
- O
induced O
activation O
of O
B O
or O
pre O
- O
B O
cells O
results O
in O
loss O
of O
I B
kappa I
B I
alpha I
from O
NF B
- I
kappa I
B I
complexes I
in O
vivo O
. O

Many O
liberated O
NF B
- I
kappa I
B I
dimers I
reached O
the O
nucleus O
, O
where O
increased O
c B
- I
rel I
, O
p65 O
and O
p50 O
were O
detected O
by O
immunoblotting O
and O
by O
DNA O
binding O
assays O
. O

Quite O
unexpectedly O
, O
we O
also O
found O
that O
in O
unstimulated O
cells O
there O
is O
a O
constant O
ongoing O
process O
of O
degradation O
and O
replacement O
of O
complexed B
I I
kappa I
B I
alpha I
. O

We O
propose O
that O
this O
turnover O
results O
in O
the O
low O
level O
of O
active B
NF I
- I
kappa I
B I
presumably O
necessary O
even O
in O
the O
unstimulated O
cell O
, O
and O
that O
the O
high O
rate O
of O
synthesis O
of O
I B
kappa I
B I
alpha I
provides O
the O
ability O
to O
turn O
off O
NF B
- I
kappa I
B I
activity O
rapidly O
as O
soon O
as O
the O
activating O
signal O
ceases O
. O

To O
understand O
the O
mechanisms O
underlying O
the O
cell O
- O
type O
- O
specific O
expression O
of O
this O
gene O
, O
we O
have O
characterized O
the O
regulatory O
functions O
and O
the O
DNA O
- O
protein O
interactions O
of O
the O
5 B
' I
- I
flanking I
region I
of O
the O
mouse B
perforin I
gene I
( O
Pfp B
) O
. O

The O
role O
of O
NF B
- I
kappa I
B1 I
( I
p50 I
/ I
p105 I
) I
gene I
expression O
in O
activation O
of O
human O
blood O
T O
- O
lymphocytes O
via O
CD2 B
and I
CD28 I
adhesion I
molecules I
. O

Stimulation O
of O
primary O
human O
T O
- O
lymphocytes O
via O
CD2 B
and I
CD28 I
adhesion I
molecules I
induces O
a O
long O
- O
lasting O
proliferation O
( O
> O
3 O
weeks O
) O
. O

Using O
electrophoretic O
mobility O
shift O
assays O
and O
Western O
and O
Northern O
blot O
analyses O
, O
we O
studied O
NF B
- I
kappa I
B1 I
gene I
expression O
during O
T O
- O
cell O
stimulation O
via O
CD2 B
+ I
CD28 I
. O

Reactive O
oxygen O
intermediates O
activate O
NF B
- I
kappa I
B I
in O
a O
tyrosine O
kinase O
- O
dependent O
mechanism O
and O
in O
combination O
with O
vanadate O
activate O
the O
p56lck B
and I
p59fyn I
tyrosine I
kinases I
in O
human O
lymphocytes O
. O

Although O
treatment O
of O
cells O
with O
H2O2 O
alone O
did O
not O
affect O
the O
activity O
of O
src B
family I
kinases I
, O
treatment O
with O
H2O2 O
plus O
vanadate O
led O
to O
activation O
of O
the O
p56lck B
and I
p59fyn I
tyrosine I
kinases I
. O

Analysis O
of O
de O
novo O
gene O
activation O
in O
multinucleated O
heterokaryons O
has O
shown O
that O
the O
differentiated O
state O
, O
although O
stable O
, O
is O
not O
irreversible O
, O
and O
can O
be O
reprogrammed O
in O
the O
presence O
of O
appropriate O
combinations O
of O
trans B
- I
acting I
regulatory I
molecules I
. O

We O
have O
tested O
whether O
breakdown O
of O
phosphatidylcholine O
( O
PC O
) O
initiated O
by O
exogenous O
addition O
of O
a O
PC B
- I
specific I
phospholipase I
C I
( O
PC B
- I
PLC I
) O
from O
Bacillus O
cereus O
or O
by O
endogenous O
overexpression O
of O
PC B
- I
PLC I
induces O
functional O
activation O
of O
NF B
- I
kappa I
B I
and O
increases O
human B
immunodeficiency I
virus I
( I
HIV I
) I
enhancer I
activity O
. O

In O
human O
monocytic O
and O
lymphoblastoid O
T O
- O
cell O
lines O
, O
induction O
of O
NF B
- I
kappa I
B I
by O
PC B
- I
PLC I
resulted O
in O
clear O
induction O
of O
luciferase B
expression O
vectors O
placed O
under O
the O
control O
of O
synthetic B
kappa I
B I
enhancers I
or O
wild O
type O
, O
but O
not O
kappa O
B O
- O
mutated O
, O
HIV B
long I
terminal I
repeat I
constructs I
. O

Interaction O
of O
IL B
- I
2 I
with O
its O
high B
affinity I
membrane I
receptor I
complex I
( O
IL B
- I
2R I
) O
present O
on O
activated O
T O
lymphocytes O
induces O
cell O
proliferation O
and O
mediates O
effector O
functions O
. O

This O
unique O
DNA O
binding O
activity O
consisted O
of O
proteins O
of O
70 B
, I
90 I
, I
and I
100 I
kDa I
with O
a O
high O
degree O
of O
binding O
specificity O
for O
the O
NF B
- I
kappa I
B I
site I
within O
the O
PRDII B
domain I
of O
beta B
interferon I
. O

DNA O
binding O
of O
the O
90 B
- I
to I
100 I
- I
kDa I
proteins I
was O
not O
inhibited O
by O
recombinant B
I I
kappa I
B I
alpha I
/ I
MAD I
- I
3 I
and O
was O
resistant O
to O
tryptic O
digestion O
, O
suggesting O
that O
these O
proteins O
may O
not O
be O
NF B
- I
kappa I
B I
related I
. O

